44_CD 44_CD Cambridg_NNP Cambridge_NNP e_SYM Antibody_NNP Antibody_NNP T_NNP Technolo_NNP echnolog_NN gy_NN y_VB Gr_NNP Group_NNP plc_NN oup_NN plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1_CD Accounting_NNP policies_NNS A_DT summary_NN of_IN the_DT principal_JJ accounting_NN policies_NNS is_VBZ set_VBN out_RP below_IN ._.
These_DT have_VBP all_DT been_VBN applied_VBN consistently_RB throughout_IN the_DT periods_NNS covered_VBN by_IN this_DT report_NN ._.
Basis_NN of_IN accounting_NN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN and_CC in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN standards_NNS in_IN the_DT United_NNP Kingdom_NNP UK_NNP GAAP_NNP ._.
Basis_NN of_IN consolidation_NN The_DT Group_NNP financial_JJ statements_NNS consolidate_VBP the_DT financial_JJ statements_NNS of_IN Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_VBP the_DT Company_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS collectively_RB the_DT Group_NNP ,_, drawn_VBN up_RP to_TO 30_CD September_NNP each_DT year_NN ._.
All_DT intercompany_NN balances_NNS and_CC transactions_NNS have_VBP been_VBN eliminated_VBN on_IN consolidation_NN ._.
The_DT acquisition_NN of_IN Cambridge_NNP Antibody_NNP Technology_NNP Limited_NNP CAT_NNP Limited_NNP ,_, by_IN way_NN of_IN share_NN for_IN share_NN exchange_NN on_IN 20_CD December_NNP 1996_CD was_VBD accounted_VBN for_IN as_IN a_DT group_NN reconstruction_NN in_IN accordance_NN with_IN Financial_NNP Reporting_NNP Standard_NNP FRS_NNP 6_CD ._.
Consequently_RB ,_, consolidated_JJ financial_JJ information_NN is_VBZ presented_VBN as_IN if_IN the_DT Company_NN has_VBZ always_RB owned_VBN CAT_NNP Limited_NNP ._.
Otherwise_RB ,_, the_DT results_NNS of_IN subsidiaries_NNS acquired_VBN are_VBP consolidated_VBN for_IN the_DT periods_NNS from_IN the_DT date_NN on_IN which_WDT control_NN passed_VBD ._.
Such_JJ acquisitions_NNS are_VBP accounted_VBN for_IN under_IN the_DT acquisition_NN method_NN ._.
The_DT results_NNS of_IN subsidiaries_NNS disposed_VBN of_IN are_VBP consolidated_VBN up_RP to_TO the_DT date_NN on_IN which_WDT control_NN passed_VBD ._.
The_DT profit_NN for_IN the_DT financial_JJ year_NN dealt_VBD with_IN in_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN was_VBD 3,090,000_CD 2001_CD :_: 7,838,000_CD ._.
As_IN provided_VBN by_IN S._NNP 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT company_NN only_RB profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN in_IN respect_NN of_IN the_DT Company_NN ._.
Goodwill_NNP Goodwill_NNP ,_, representing_VBG the_DT excess_NN of_IN fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS and_CC liabilities_NNS acquired_VBN ,_, is_VBZ capitalized_VBN as_IN an_DT asset_NN on_IN the_DT balance_NN sheet_NN ._.
On_IN disposal_NN of_IN a_DT previously_RB acquired_VBN business_NN ,_, the_DT attributable_JJ amount_NN of_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS under_IN the_DT then_RB applicable_JJ accounting_NN policy_NN is_VBZ included_VBN in_IN determining_VBG the_DT profit_NN or_CC loss_NN on_IN disposal_NN ._.
Turnover_NN Turnover_NN principally_RB consists_VBZ of_IN income_NN received_VBN in_IN the_DT normal_JJ course_NN of_IN business_NN from_IN license_NN fees_NNS ,_, technical_JJ milestones_NNS ,_, clinical_JJ milestones_NNS ,_, fees_NNS for_IN research_NN and_CC development_NN services_NNS ,_, payments_NNS for_IN purchased_VBN rights_NNS ,_, and_CC royalties_NNS ._.
These_DT are_VBP stated_VBN net_NN of_IN trade_NN discounts_NNS ,_, VAT_NNP and_CC other_JJ sales_NNS related_VBN taxes_NNS ._.
A_DT description_NN of_IN the_DT various_JJ elements_NNS of_IN turnover_NN and_CC their_PRP$ accounting_NN policies_NNS is_VBZ given_VBN below_IN ._.
Licence_NN fees_NNS Licence_NNP fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN where_WRB relevant_JJ ._.
In_IN circumstances_NNS where_WRB no_DT such_JJ defined_VBN period_NN exists_VBZ ,_, the_DT licence_NN fee_NN is_VBZ deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO expiration_NN of_IN the_DT relevant_JJ patents_NNS licenced_VBD ._.
For_IN licence_NN fees_NNS where_WRB a_DT proportion_NN of_IN the_DT fee_NN is_VBZ creditable_JJ against_IN research_NN and_CC development_NN services_NNS to_TO be_VB provided_VBN in_IN the_DT future_NN that_WDT proportion_NN of_IN the_DT amount_NN received_VBN is_VBZ deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN during_IN which_WDT the_DT services_NNS are_VBP rendered_VBN ._.
Technical_NNP milestones_NNS During_IN certain_JJ research_NN and_CC development_NN programs_NNS the_DT Group_NNP receives_VBZ non-refundable_JJ milestone_NN payments_NNS when_WRB it_PRP achieves_VBZ certain_JJ defined_VBN technical_JJ criteria_NNS ._.
Such_JJ milestones_NNS are_VBP recognized_VBN based_VBN on_IN the_DT percentage_NN of_IN completion_NN of_IN the_DT relevant_JJ research_NN and_CC development_NN program_NN subject_NN to_TO the_DT total_JJ revenue_NN recognized_VBN being_VBG limited_VBN to_TO the_DT aggregate_JJ amount_NN of_IN non-refundable_JJ milestone_NN payments_NNS received_VBD ._.
The_DT percentage_NN completion_NN is_VBZ determined_VBN by_IN reference_NN to_TO effort_NN in_IN hours_NNS incurred_VBN compared_VBN to_TO total_JJ estimated_JJ effort_NN for_IN the_DT program_NN ._.
Clinical_JJ milestones_NNS The_DT Group_NNP receives_VBZ non-refundable_JJ clinical_JJ development_NN milestones_NNS when_WRB a_DT licensee_NN or_CC corporate_JJ partner_NN achieves_VBZ key_JJ stages_NNS in_IN clinical_JJ trials_NNS which_WDT they_PRP are_VBP conducting_VBG with_IN a_DT view_NN to_TO the_DT ultimate_JJ commercialisation_NN of_IN a_DT product_NN derived_VBN using_VBG the_DT Groups_NNS proprietary_JJ technology_NN ._.
Such_JJ milestones_NNS are_VBP recognized_VBN when_WRB received_VBN except_IN that_DT if_IN such_JJ milestones_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS a_DT relevant_JJ amount_NN will_MD be_VB deferred_VBN and_CC released_VBN as_IN the_DT related_JJ royalty_NN payments_NNS are_VBP received_VBN ._.
Research_NNP and_CC development_NN services_NNS The_DT Group_NNP provides_VBZ research_NN and_CC development_NN services_NNS to_TO certain_JJ corporate_JJ collaborators_NNS ,_, usually_RB in_IN the_DT form_NN of_IN a_DT defined_VBN number_NN of_IN the_DT Groups_NNS employees_NNS working_VBG under_IN the_DT direction_NN of_IN the_DT collaborator_NN to_TO further_VB the_DT collaborators_NNS research_NN and_CC development_NN effort_NN ._.
Such_JJ contracts_NNS are_VBP made_VBN on_IN the_DT basis_NN of_IN Full_NNP Time_NNP Equivalent_NNP FTE_NNP employees_NNS and_CC are_VBP charged_VBN at_IN a_DT specified_VBN rate_NN per_IN FTE_NNP ._.
Revenues_NNS from_IN FTE_NNP services_NNS are_VBP recognized_VBN as_IN the_DT services_NNS are_VBP rendered_VBN ._.
Purchased_VBN rights_NNS Under_IN an_DT agreement_NN with_IN Drug_NNP Royalty_NNP Corporation_NNP DRC_NNP the_DT Group_NNP received_VBD a_DT payment_NN of_IN 1.5_CD million_CD in_IN 1994_CD in_IN return_NN for_IN rights_NNS to_TO a_DT percentage_NN of_IN revenues_NNS and_CC certain_JJ other_JJ payments_NNS received_VBN by_IN the_DT Group_NNP over_IN a_DT period_NN terminating_VBG in_IN 2009_CD ._.
The_DT Groups_NNS accounting_VBG policy_NN is_VBZ that_IN the_DT payment_NN be_VB deferred_VBN and_CC recognized_VBN ratably_RB over_IN the_DT period_NN for_IN which_WDT rights_NNS were_VBD purchased_VBN ._.
On_IN 2_CD May_NNP 2002_CD the_DT Group_NNP bought_VBD out_RP this_DT royalty_NN obligation_NN with_IN the_DT issue_NN of_IN CAT_NNP shares_NNS to_TO DRC_NNP ._.
The_DT remaining_VBG balance_NN of_IN deferred_JJ income_NN has_VBZ been_VBN released_VBN in_IN the_DT year_NN ended_VBD 30_CD September_NNP 2002_CD ._.
Royalties_NNS Royalty_NN income_NN is_VBZ generated_VBN by_IN sales_NNS of_IN products_NNS incorporating_VBG the_DT Groups_NNS proprietary_JJ technology_NN and_CC is_VBZ recognized_VBN when_WRB received_VBN ._.
The_DT Group_NNP has_VBZ yet_RB to_TO receive_VB any_DT significant_JJ royalty_NN payments_NNS ._.
45_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Government_NN grants_NNS Grants_NNPS of_IN a_DT revenue_NN nature_NN are_VBP credited_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN the_DT related_JJ expenditure_NN is_VBZ incurred_VBN ._.
Taxation_NNP Current_NNP tax_NN ,_, including_VBG UK_NNP corporation_NN tax_NN and_CC foreign_JJ tax_NN ,_, is_VBZ provided_VBN at_IN amounts_NNS expected_VBN to_TO be_VB paid_VBN or_CC recovered_VBN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT have_VBP been_VBN enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Company_NN has_VBZ adopted_VBN FRS_NNP 19_CD Deferred_NNP Tax_NNP ._.
Deferred_JJ tax_NN is_VBZ provided_VBN in_IN full_JJ on_IN timing_NN differences_NNS which_WDT result_VBP in_IN an_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN to_TO pay_VB more_JJR tax_NN ,_, or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN ,_, at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN a_DT current_JJ tax_NN rates_NNS and_CC law_NN ._.
Timing_NN differences_NNS arise_VBP from_IN the_DT inclusion_NN of_IN items_NNS of_IN income_NN and_CC expenditure_NN in_IN taxation_NN computations_NNS in_IN periods_NNS different_JJ from_IN those_DT in_IN which_WDT they_PRP are_VBP included_VBN in_IN financial_JJ statements_NNS ._.
Deferred_JJ tax_NN is_VBZ not_RB provided_VBN on_IN timing_NN differences_NNS arising_VBG from_IN the_DT revaluation_NN of_IN fixed_JJ assets_NNS where_WRB there_EX is_VBZ no_DT commitment_NN to_TO sell_VB the_DT asset_NN ,_, or_CC on_IN unremitted_JJ earnings_NNS of_IN subsidiaries_NNS and_CC associates_NNS where_WRB there_EX is_VBZ no_DT commitment_NN to_TO remit_VB these_DT earnings_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
Research_NNP and_CC development_NN Research_NN and_CC development_NN expenditure_NN is_VBZ written_VBN off_RP as_IN incurred_VBN ._.
Collaboration_NNP arrangements_NNS The_DT Group_NNP has_VBZ entered_VBN into_IN certain_JJ collaboration_NN arrangements_NNS whereby_WRB the_DT parties_NNS agree_VBP to_TO work_VB jointly_RB on_IN research_NN and_CC development_NN of_IN potential_JJ therapeutic_JJ products_NNS ._.
Under_IN such_JJ arrangements_NNS the_DT parties_NNS agree_VBP which_WDT elements_NNS of_IN research_NN and_CC development_NN each_DT will_MD perform_VB ._.
These_DT arrangements_NNS do_VBP not_RB include_VB the_DT creation_NN of_IN any_DT separate_JJ entity_NN to_TO conduct_VB the_DT activities_NNS nor_CC any_DT separate_JJ and_CC distinct_JJ assets_NNS or_CC liabilities_NNS ._.
The_DT parties_NNS agree_VBP that_IN the_DT combined_VBN cost_NN of_IN all_DT relevant_JJ activities_NNS will_MD be_VB borne_VBN by_IN the_DT parties_NNS in_IN a_DT particular_JJ proportion_NN and_CC that_IN net_JJ revenues_NNS derived_VBN from_IN sales_NNS of_IN any_DT resulting_VBG product_NN will_MD be_VB shared_VBN similarly_RB ._.
The_DT sharing_NN of_IN costs_NNS will_MD result_VB in_IN balancing_VBG payments_NNS between_IN the_DT parties_NNS and_CC such_JJ payments_NNS receivable_JJ or_CC payable_JJ will_MD be_VB respectively_RB added_VBN to_TO or_CC deducted_VBN from_IN research_NN and_CC development_NN costs_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Any_DT amounts_NNS receivable_JJ or_CC payable_JJ at_IN a_DT period_NN end_NN are_VBP included_VBN in_IN the_DT balance_NN sheet_NN under_IN debtors_NNS or_CC creditors_NNS ._.
Pension_NN costs_NNS The_DT Group_NNP operates_VBZ a_DT group_NN personal_JJ pension_NN plan_NN which_WDT is_VBZ a_DT defined_VBN contribution_NN scheme_NN ._.
The_DT amount_NN charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN respect_NN of_IN pension_NN costs_NNS is_VBZ the_DT Groups_NNS contributions_NNS payable_JJ in_IN the_DT year_NN ._.
Differences_NNS between_IN contributions_NNS payable_JJ in_IN the_DT year_NN and_CC contributions_NNS actually_RB paid_VBN are_VBP shown_VBN as_IN either_DT accruals_NNS or_CC prepayments_NNS in_IN the_DT balance_NN sheet_NN ._.
Intangible_JJ assets_NNS Purchased_VBN intangible_JJ assets_NNS excluding_VBG goodwill_NN are_VBP capitalized_VBN as_IN assets_NNS on_IN the_DT balance_NN sheet_NN at_IN fair_JJ value_NN on_IN acquisition_NN and_CC amortised_VBN over_IN their_PRP$ useful_JJ economic_JJ lives_NNS ,_, subject_JJ to_TO reviews_NNS for_IN impairment_NN when_WRB events_NNS or_CC change_NN of_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ using_VBG cash_NN flow_NN projections_NNS ._.
To_TO the_DT extent_NN carrying_VBG values_NNS exceed_VBP fair_JJ values_NNS ,_, an_DT impairment_NN is_VBZ recognized_VBN and_CC charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN that_DT period_NN ._.
This_DT applies_VBZ to_TO intangibles_NNS purchased_VBN separately_RB from_IN a_DT business_NN and_CC also_RB to_TO intangibles_NNS acquired_VBN as_IN part_NN of_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, if_IN their_PRP$ value_NN can_MD be_VB measured_VBN reliably_RB on_IN initial_JJ recognition_NN ._.
The_DT Groups_NNS purchased_VBD intangible_JJ assets_NNS include_VBP access_NN to_TO intellectual_JJ property_NN and_CC options_NNS for_IN product_NN development_NN rights_NNS which_WDT are_VBP being_VBG amortised_VBN over_IN seven_CD years_NNS and_CC also_RB include_VBP certain_JJ patents_NNS which_WDT are_VBP being_VBG written_VBN off_RP over_IN their_PRP$ term_NN to_TO expiry_VB which_WDT is_VBZ between_IN 12_CD and_CC 16_CD years_NNS from_IN the_DT date_NN of_IN acquisition_NN ._.
When_WRB reviewing_VBG all_PDT these_DT assets_NNS for_IN impairment_NN the_DT Directors_NNS have_VBP considered_VBN future_JJ cash_NN flows_VBZ arising_VBG ._.
Tangible_JJ fixed_JJ assets_NNS Tangible_JJ fixed_VBN assets_NNS are_VBP stated_VBN at_IN cost_NN ,_, net_NN of_IN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN all_DT tangible_JJ fixed_JJ assets_NNS other_JJ than_IN freehold_JJ land_NN on_IN a_DT straight-line_JJ basis_NN at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN ,_, less_JJR estimated_VBN residual_JJ value_NN ,_, of_IN each_DT asset_NN over_IN its_PRP$ expected_VBN useful_JJ life_NN as_IN follows_VBZ :_: Freehold_NNP buildings_NNS :_: over_IN 12_CD years_NNS ._.
Office_NNP and_CC laboratory_NN equipment_NN :_: 25_CD %_NN per_IN annum_NN ._.
Fixtures_NNS and_CC fittings_NNS :_: over_IN either_DT 5_CD or_CC 20_CD years_NNS or_CC the_DT remaining_VBG lease_NN term_NN if_IN less_JJR ._.
Investments_NNP Fixed_NNP asset_NN investments_NNS are_VBP shown_VBN at_IN cost_NN less_JJR provision_NN for_IN any_DT impairment_NN ._.
Liquid_NN resources_NNS Liquid_NN resources_NNS comprise_VBP negotiable_JJ securities_NNS and_CC term_NN deposits_NNS and_CC are_VBP shown_VBN at_IN cost_NN with_IN accrued_VBN interest_NN included_VBN in_IN debtors_NNS ._.
Where_WRB relevant_JJ a_DT provision_NN is_VBZ made_VBN such_JJ that_IN cost_NN plus_CC accrued_VBN interest_NN does_VBZ not_RB exceed_VB market_NN value_NN ._.
46_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1_CD Accounting_NNP policies_NNS continued_VBD Foreign_JJ currency_NN Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN at_IN the_DT rate_NN of_IN exchange_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS at_IN the_DT balance_NN sheet_NN date_NN are_VBP reported_VBN at_IN the_DT rates_NNS of_IN exchange_NN prevailing_VBG at_IN that_DT date_NN ._.
Any_DT gain_NN or_CC loss_NN arising_VBG from_IN a_DT change_NN in_IN exchange_NN rates_NNS subsequent_JJ to_TO the_DT date_NN of_IN the_DT transaction_NN is_VBZ included_VBN as_IN an_DT exchange_NN gain_NN or_CC loss_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS and_CC their_PRP$ balance_NN sheets_NNS are_VBP translated_VBN at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS arising_VBG on_IN translation_NN of_IN the_DT opening_NN net_JJ assets_NNS and_CC results_NNS of_IN overseas_JJ operations_NNS are_VBP dealt_VBN with_IN through_IN reserves_NNS ._.
Leases_NNS Assets_NNS held_VBN under_IN finance_NN leases_NNS ,_, which_WDT confer_VBP rights_NNS and_CC obligations_NNS similar_JJ to_TO those_DT attached_VBN to_TO owned_VBN assets_NNS ,_, are_VBP capitalized_VBN as_IN tangible_JJ fixed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT lease_NN terms_NNS and_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN obligations_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN elements_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN of_IN the_DT leases_NNS to_TO produce_VB a_DT constant_JJ rate_NN of_IN charge_NN on_IN the_DT balance_NN of_IN capital_NN repayments_NNS outstanding_JJ ._.
Hire_VB purchase_NN transactions_NNS are_VBP dealt_VBN with_IN similarly_RB ,_, except_IN that_DT assets_NNS are_VBP depreciated_VBN over_IN their_PRP$ useful_JJ lives_NNS ._.
Rentals_NNS under_IN operating_VBG leases_NNS are_VBP charged_VBN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN even_RB if_IN payments_NNS are_VBP made_VBN on_IN another_DT basis_NN ._.
Estimates_NNS and_CC assumptions_NNS The_DT preparation_NN of_IN financial_JJ statements_NNS in_IN conformity_NN with_IN generally_RB accepted_VBN accounting_NN standards_NNS requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC disclosures_NNS of_IN contingent_JJ assets_NNS and_CC liabilities_NNS as_IN of_IN the_DT dates_NNS of_IN the_DT financial_JJ statements_NNS and_CC the_DT reported_VBN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT year_NN ._.
In_IN the_DT preparation_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ,_, estimates_NNS and_CC assumptions_NNS have_VBP been_VBN made_VBN by_IN management_NN concerning_VBG the_DT selection_NN of_IN useful_JJ lives_NNS of_IN fixed_JJ assets_NNS ,_, provisions_NNS necessary_JJ for_IN certain_JJ liabilities_NNS ,_, the_DT carrying_VBG value_NN of_IN investments_NNS ,_, the_DT recoverability_NN of_IN deferred_JJ tax_NN assets_NNS and_CC other_JJ similar_JJ evaluations_NNS ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
2_CD Turnover_NN and_CC loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN Turnover_NN and_CC loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN relate_VBP solely_RB to_TO the_DT principal_JJ activity_NN and_CC are_VBP attributable_JJ to_TO the_DT continuing_VBG operations_NNS of_IN the_DT Group_NNP substantially_RB all_DT of_IN which_WDT take_VBP place_NN in_IN the_DT United_NNP Kingdom_NNP ._.
Turnover_NN principally_RB consists_VBZ of_IN licence_NN fees_NNS ,_, milestone_NN payments_NNS and_CC fees_NNS for_IN research_NN and_CC development_NN services_NNS provided_VBN under_IN corporate_JJ agreements_NNS ._.
2002 2001 2000 000_CD 000_CD 000_CD Total_JJ turnover_NN 16,891_CD 9,421_CD 7,018_CD Less_RBR :_: intra-group_JJ eliminations_NNS 7,420_CD 2,300_CD Consolidated_NNP turnover_NN 9,471_CD 7,121_CD 7,018_CD Consolidated_NNP turnover_NN was_VBD generated_VBN from_IN customers_NNS in_IN the_DT following_VBG geographical_JJ areas_NNS :_: 2002 2001 2000 000_CD 000_CD 000_CD United_NNP Kingdom_NNP 316_CD Rest_VB of_IN Europe_NNP 135_CD 53_CD 1,104_CD United_NNP States_NNPS of_IN America_NNP 8,674_CD 6,969_CD 5,598_CD Rest_VBP of_IN World_NNP 662_CD 99_CD 9,471_CD 7,121_CD 7,018_CD Net_JJ liabilities_NNS of_IN 349,000_CD excluding_VBG creditors_NNS eliminated_VBN on_IN consolidation_NN of_IN 9,210,000_CD 2001_CD :_: net_JJ assets_NNS of_IN 643,000_CD ,_, excluding_VBG creditors_NNS eliminated_VBN on_IN consolidation_NN of_IN 2,387,000_CD and_CC total_JJ assets_NNS of_IN 549,000_CD 2001_CD :_: 643,000_CD are_VBP held_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
47_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 2_CD Turnover_NN and_CC loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN continued_VBD Consolidated_NNP turnover_NN by_IN type_NN :_: 2002 2001 2000 000_CD 000_CD 000_CD Licence_NN fees_NNS 1,676_CD 1,635_CD 699_CD Technical_NNP milestones_NNS 35_CD 652_CD Clinical_JJ milestones_NNS 1,396_CD 1,000_CD Contract_NNP research_NN fees_NNS 5,611_CD 5,369_CD 4,536_CD Other_JJ 753 117 131_CD Total_JJ 9,471_CD 7,121_CD 7,018_CD During_IN the_DT financial_JJ years_NNS ended_VBN 30_CD September_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD certain_JJ customers_NNS individually_RB contributed_VBD more_JJR than_IN 10_CD %_NN of_IN the_DT Groups_NNS revenue_NN in_IN each_DT year_NN ._.
The_DT amounts_NNS of_IN those_DT individual_JJ contributions_NNS in_IN order_NN of_IN size_NN by_IN year_NN were_VBD as_IN follows_VBZ :_: %_NN 000_CD 2002_CD Customer_NN contributing_VBG greatest_JJS %_NN to_TO revenue_NN 36_CD 3,424_CD 2002_CD Customer_NN contributing_VBG second_JJ greatest_JJS %_NN to_TO revenue_NN 31_CD 2,954_CD Total_JJ 67_CD 6,378_CD 2001_CD Customer_NN contributing_VBG greatest_JJS %_NN to_TO revenue_NN 31_CD 2,230_CD 2001_CD Customer_NN contributing_VBG second_JJ greatest_JJS %_NN to_TO revenue_NN 30_CD 2,101_CD 2001_CD Customer_NN contributing_VBG third_JJ greatest_JJS %_NN to_TO revenue_NN 24_CD 1,742_CD Total_JJ 85_CD 6,073_CD 2000_CD Customer_NN contributing_VBG greatest_JJS %_NN to_TO revenue_NN 37_CD 2,609_CD 2000_CD Customer_NN contributing_VBG second_JJ greatest_JJS %_NN to_TO revenue_NN 20_CD 1,425_CD 2000_CD Customer_NN contributing_VBG third_JJ greatest_JJS %_NN to_TO revenue_NN 15_CD 1,050_CD 2000_CD Customer_NN contributing_VBG fourth_JJ greatest_JJS %_NN to_TO revenue_NN 14_CD 1,000_CD Total_JJ 86_CD 6,084_CD As_IN at_IN 30_CD September_NNP 2002_CD ,_, the_DT two_CD customers_NNS shown_VBN above_IN constituted_VBN 89_CD %_NN of_IN the_DT Groups_NNS trade_VBP receivables_NN ._.
As_IN at_IN 30_CD September_NNP 2001_CD the_DT three_CD customers_NNS shown_VBN above_IN constituted_VBN 96_CD %_NN of_IN the_DT Groups_NNS trade_VBP receivables_NN ._.
3_CD Drug_NN Royalty_NN transaction_NN costs_NNS General_NNP and_CC administration_NN expenses_NNS include_VBP 7.9_CD million_CD of_IN costs_NNS incurred_VBN in_IN the_DT year_NN relating_VBG to_TO the_DT two_CD transactions_NNS entered_VBD into_IN with_IN DRC_NNP during_IN the_DT year_NN comparative_JJ periods_NNS :_: none_NN ._.
In_IN January_NNP 2002_CD ,_, the_DT Group_NNP announced_VBD a_DT recommended_VBN offer_NN for_IN the_DT whole_NN of_IN DRC_NNP ._.
A_DT competing_VBG offer_NN was_VBD made_VBN by_IN Inwest_NNP Investments_NNPS Ltd_NNP of_IN Canada_NNP which_WDT was_VBD accepted_VBN in_IN April_NNP 2002_CD ._.
Under_IN an_DT agreement_NN with_IN DRC_NNP ,_, the_DT Group_NNP received_VBD a_DT payment_NN of_IN 1.5_CD million_CD in_IN 1994_CD in_IN return_NN for_IN rights_NNS to_TO a_DT percentage_NN of_IN revenues_NNS and_CC certain_JJ other_JJ payments_NNS received_VBN by_IN the_DT Group_NNP over_IN a_DT period_NN terminating_VBG in_IN 2009_CD ._.
On_IN 2_CD May_NNP 2002_CD ,_, the_DT Group_NNP bought_VBD out_RP this_DT royalty_NN obligation_NN to_TO DRC_NNP for_IN consideration_NN of_IN 6.1_CD million_CD CAD$_NNP 14_CD million_CD with_IN the_DT issue_NN of_IN 463,818_CD CAT_NNP shares_NNS to_TO DRC_NNP ._.
The_DT remaining_VBG balance_NN of_IN 0.6_CD million_CD of_IN deferred_JJ income_NN has_VBZ all_DT been_VBN released_VBN to_TO turnover_NN in_IN the_DT period_NN ._.
The_DT professional_JJ fees_NNS incurred_VBN in_IN the_DT Groups_NNS bid_NN and_CC royalty_NN buy-back_NN were_VBD 1.8_CD million_CD ._.
48_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 4_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 2002 2001 2000 000_CD 000_CD 000_CD The_DT loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN is_VBZ stated_VBN after_IN charging_VBG crediting_VBG :_: Depreciation_NN and_CC amounts_NNS written_VBN off_RP owned_VBN tangible_JJ fixed_JJ assets_NNS :_: 2,617_CD 2,146_CD 1,808_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS 882 373 374_CD Auditors_NNS remuneration_JJ audit_NN Deloitte_NNP &_CC Touche_NNP 35_CD audit_NN Arthur_NNP Andersen_NNP 42_CD 27_CD other_JJ assurance_NN Deloitte_NNP &_CC Touche_NNP 19_CD other_JJ Deloitte_NNP &_CC Touche_NNP 9_CD other_JJ Arthur_NNP Andersen_NNP 287 149 219_CD Foreign_JJ exchange_NN loss_NN gain_NN 192_CD 56_CD 123_CD Profit_NN on_IN disposal_NN of_IN Denzyme_NNP ApS_NNP 2_CD Operating_NN lease_NN rentals_NNS :_: plant_NN and_CC machinery_NN 5_CD 33_CD other_JJ operating_VBG leases_NNS 874 721 290_CD Allocations_NNS under_IN equity_NN participation_NN schemes_NNS 607 416 459_CD Arthur_NNP Andersen_NNP resigned_VBD as_IN auditors_NNS to_TO the_DT Group_NNP on_IN 17_CD May_NNP 2002_CD and_CC were_VBD replaced_VBN by_IN Deloitte_NNP &_CC Touche_NNP ._.
5_CD Interest_NN receivable_NN 2002 2001 2000 000_CD 000_CD 000_CD Interest_NN receivable_NN 6,386_CD 9,295_CD 5,644_CD 6_CD Staff_NN costs_NNS The_DT average_JJ monthly_JJ number_NN of_IN persons_NNS including_VBG Executive_NNP Directors_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD :_: 2002 2001 2000_CD Management_NN and_CC administration_NN 39_CD 32_CD 22_CD Research_NNP and_CC development_NN 235 192 139 274_CD 224 161 000 000_CD 000_CD Their_PRP$ aggregate_JJ remuneration_NN comprised_VBN :_: Wages_NNS and_CC salaries_NNS 9,771_CD 7,268_CD 5,233_CD Social_NNP security_NN costs_NNS credit_NN charge_NN provided_VBN on_IN unapproved_JJ options_NNS 248 194 523_CD on_IN wages_NNS and_CC salaries_NNS 970 740 527_CD Other_JJ pension_NN costs_NNS 875 641 432_CD 11,368_CD 8,455_CD 6,715_CD Further_JJ audited_JJ information_NN on_IN Directors_NNS remuneration_NN is_VBZ contained_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
The_DT Group_NNP has_VBZ made_VBN a_DT provision_NN for_IN employers_NNS National_NNP Insurance_NNP payable_JJ on_IN certain_JJ options_NNS granted_VBN under_IN the_DT CSOP_NNP Part_NNP B_NNP scheme_NN in_IN December_NNP 1999_CD ._.
The_DT liability_NN will_MD not_RB crystallise_VB until_IN the_DT options_NNS are_VBP exercised_VBN they_PRP are_VBP exercisable_JJ from_IN December_NNP 2002_CD and_CC the_DT ultimate_JJ liability_NN will_MD be_VB determined_VBN by_IN the_DT difference_NN between_IN the_DT exercise_NN price_NN paid_VBN by_IN the_DT employee_NN and_CC the_DT market_NN price_NN on_IN exercise_NN and_CC on_IN the_DT then_RB prevailing_VBG rate_NN for_IN employers_NNS contributions_NNS ._.
49_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 6_CD Staff_NN costs_NNS continued_VBD The_DT options_NNS are_VBP exercisable_JJ subject_NN to_TO the_DT condition_NN that_IN the_DT proportionate_NN increase_NN in_IN the_DT closing_NN price_NN of_IN shares_NNS in_IN the_DT Company_NN over_IN a_DT specified_JJ period_NN must_MD exceed_VB the_DT proportionate_NN increase_NN in_IN the_DT total_JJ return_NN on_IN the_DT FTSE_NNP All_NNP Share_NNP Index_NNP ._.
The_DT specified_JJ period_NN begins_VBZ on_IN the_DT date_NN of_IN grant_NN and_CC ends_VBZ between_IN the_DT third_JJ and_CC fourth_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN ._.
The_DT provision_NN is_VBZ being_VBG made_VBN systematically_RB by_IN reference_NN to_TO the_DT market_NN value_NN of_IN the_DT shares_NNS at_IN the_DT balance_NN sheet_NN dates_NNS over_IN the_DT period_NN from_IN the_DT date_NN of_IN grant_NN to_TO the_DT end_NN of_IN the_DT performance_NN period_NN ,_, and_CC from_IN that_DT date_NN to_TO the_DT date_NN of_IN actual_JJ exercise_NN the_DT provision_NN will_MD be_VB adjusted_VBN by_IN reference_NN to_TO changes_NNS in_IN market_NN value_NN ._.
For_IN this_DT purpose_NN the_DT performance_NN period_NN is_VBZ assumed_VBN to_TO be_VB of_IN minimum_JJ duration_NN ._.
The_DT provision_NN and_CC corresponding_JJ charges_NNS to_TO the_DT profit_NN and_CC loss_NN account_NN will_MD be_VB affected_VBN by_IN :_: the_DT elapse_NN of_IN performance_NN periods_NNS :_: the_DT remaining_VBG number_NN and_CC option_NN price_NN of_IN shares_NNS under_IN option_NN :_: and_CC ,_, the_DT market_NN value_NN of_IN the_DT shares_NNS ._.
The_DT market_NN price_NN of_IN shares_NNS at_IN the_DT year_NN end_NN was_VBD 4.64_CD ._.
If_IN that_DT price_NN and_CC the_DT relevant_JJ number_NN of_IN shares_NNS under_IN option_NN remained_VBD unchanged_JJ ,_, the_DT charge_NN for_IN a_DT further_JJ year_NN would_MD amount_VB to_TO 5,000_CD ._.
If_IN the_DT market_NN value_NN of_IN the_DT shares_NNS were_VBD to_TO increase_VB by_IN 10_CD %_NN over_IN that_DT at_IN the_DT year_NN end_NN ,_, the_DT charge_NN would_MD increase_VB by_IN 22,000_CD ._.
7_CD Taxation_NNP 2002 2001 2000 000_CD 000_CD 000_CD Research_NNP and_CC development_NN tax_NN credit_NN 3,557_CD During_IN the_DT year_NN ended_VBD 30_CD September_NNP 2002_CD the_DT Group_NNP received_VBD a_DT refund_NN of_IN 920,000_CD in_IN respect_NN of_IN the_DT surrender_NN of_IN tax_NN losses_NNS created_VBN through_IN research_NN and_CC development_NN for_IN the_DT year_NN ended_VBD 30_CD September_NNP 2000_CD ._.
A_DT similar_JJ claim_NN has_VBZ been_VBN made_VBN for_IN the_DT year_NN ended_VBD 30_CD September_NNP 2001_CD ,_, which_WDT is_VBZ reflected_VBN in_IN other_JJ debtors_NNS at_IN 30_CD September_NNP 2002_CD ,_, and_CC for_IN which_WDT the_DT Group_NNP received_VBD a_DT refund_NN of_IN 2,637,000_CD in_IN October_NNP 2002_CD ._.
The_DT tax_NN assessed_VBN for_IN the_DT year_NN differs_VBZ from_IN that_DT resulting_VBG from_IN applying_VBG the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP of_IN 30_CD %_NN 2001_CD :_: 30_CD %_NN ._.
The_DT differences_NNS are_VBP explained_VBN below_IN :_: 2002 2001 000 000_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN 31,764_CD 11,771_CD Tax_NNP at_IN 30_CD %_NN thereon_NN 9,529_CD 3,531_CD Effects_NNPS of_IN :_: Increase_VB in_IN losses_NNS carried_VBD forward_RB 11,400_CD 5,071_CD Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 1,041_CD 1,205_CD Capital_NN allowances_NNS in_IN excess_NN of_IN depreciation_NN 888_CD 335_CD Utilisation_NN of_IN tax_NN losses_NNS in_IN respect_NN of_IN research_NN and_CC development_NN tax_NN credit_NN 3,557_CD Movement_NNP in_IN short_JJ term_NN timing_NN differences_NNS 58_CD 3,557_CD Analysis_NN of_IN deferred_JJ tax_NN balances_NNS :_: 2002 2001 000 000_CD Short_JJ term_NN timing_NN differences_NNS 58_CD Accelerated_VBN capital_NN allowances_NNS 1,272_CD 335_CD Tax_NNP losses_NNS available_JJ 23,658_CD 18,126_CD Total_JJ unprovided_JJ deferred_JJ tax_NN asset_NN 22,444_CD 18,461_CD At_IN 30_CD September_NNP 2002_CD the_DT Group_NNP had_VBD tax_NN losses_NNS of_IN approximately_RB 79_CD million_CD 2001_CD :_: 60_CD million_CD ,_, 2000_CD :_: 36_CD million_CD available_JJ for_IN relief_NN against_IN future_JJ taxable_JJ profits_NNS ._.
Due_JJ to_TO the_DT availability_NN of_IN tax_NN losses_NNS there_EX is_VBZ no_DT provision_NN for_IN deferred_VBN taxation_NN ._.
A_DT deferred_JJ tax_NN asset_NN amounting_VBG to_TO 24_CD million_CD representing_VBG such_JJ losses_NNS has_VBZ not_RB been_VBN recognized_VBN ._.
The_DT deferred_JJ tax_NN asset_NN would_MD become_VB recoverable_JJ should_MD the_DT Group_NNP generate_VB relevant_JJ taxable_JJ profits_NNS against_IN which_WDT the_DT tax_NN losses_NNS would_MD be_VB offset_VBN ._.
The_DT adoption_NN of_IN FRS_NNP 19_CD Deferred_NNP Tax_NNP by_IN the_DT Group_NNP has_VBZ no_DT effect_NN on_IN prior_JJ periods_NNS ._.
50_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNPS 8_CD Loss_NN per_IN share_NN Basic_JJ net_JJ loss_NN per_IN share_NN is_VBZ calculated_VBN by_IN dividing_VBG net_JJ loss_NN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN ._.
The_DT computation_NN of_IN diluted_JJ net_JJ loss_NN per_IN share_NN reflects_VBZ the_DT potential_JJ dilution_NN that_WDT could_MD occur_VB if_IN dilutive_JJ securities_NNS and_CC other_JJ contracts_NNS to_TO issue_VB ordinary_JJ shares_NNS were_VBD exercised_VBN or_CC converted_VBN into_IN ordinary_JJ shares_NNS or_CC resulted_VBD in_IN the_DT issue_NN of_IN ordinary_JJ shares_NNS that_WDT then_RB shared_VBD in_IN the_DT net_JJ loss_NN of_IN the_DT Group_NNP ._.
Potentially_RB dilutive_JJ issuable_JJ shares_NNS are_VBP included_VBN in_IN the_DT calculation_NN of_IN diluted_JJ loss_NN per_IN share_NN if_IN their_PRP$ issue_NN would_MD increase_VB net_JJ loss_NN per_IN share_NN or_CC decrease_NN net_JJ profit_NN per_IN share_NN ._.
Since_IN the_DT Group_NNP has_VBZ reported_VBN losses_NNS ,_, its_PRP$ basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN are_VBP therefore_RB equal_JJ ._.
For_IN the_DT years_NNS ending_VBG 30_CD September_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD 867,316_CD ,_, 1,077,800_CD and_CC 1,548,764_CD potentially_RB dilutive_JJ issuable_JJ shares_NNS attributable_JJ to_TO the_DT exercise_NN of_IN outstanding_JJ options_NNS were_VBD excluded_VBN from_IN the_DT calculation_NN of_IN diluted_JJ loss_NN per_IN share_NN ._.
No_DT adjustments_NNS were_VBD made_VBN to_TO reported_VBN net_JJ loss_NN in_IN the_DT computation_NN of_IN net_JJ loss_NN per_IN share_NN ._.
11_CD Fixed_JJ asset_NN investments_NNS Group_NNP Company_NNP Other_JJ Subsidiary_NNP investments_NNS undertakings_NNS 000_CD 000_CD Cost_NN and_CC net_JJ book_NN value_NN At_IN 1_CD October_NNP 2001_CD 101,456_CD Additions_NNPS 215_CD At_IN 30_CD September_NNP 2002 215 101_CD ,456_CD The_DT subsidiary_NN undertakings_NNS of_IN the_DT Company_NN ,_, all_DT of_IN which_WDT are_VBP consolidated_JJ ,_, are_VBP as_IN follows_VBZ :_: Country_NN of_IN incorporation_NN Principal_NN Percentage_NN of_IN and_CC operation_NN activity_NN ordinary_JJ shares_NNS held_VBD Cambridge_NNP Antibody_NNP Technology_NNP Limited_NNP England_NNP Research_NNP and_CC development_NN 100_CD %_NN CAT_NNP Group_NNP EmployeesTrustees_NNP Limited_NNP England_NNP Share_NNP scheme_NN trust_NN company_NN 100_CD %_NN Optein_NNP Inc._NNP trading_NN as_IN Aptein_NNP Inc._NNP ._.
USA_NNP Research_NNP and_CC development_NN 100_CD %_NN During_IN the_DT period_NN the_DT Group_NNP disposed_VBD of_IN its_PRP$ wholly_RB owned_VBN subsidiary_NN ,_, Denzyme_NNP ApS_NNP ,_, in_IN return_NN for_IN a_DT minority_NN interest_NN in_IN another_DT company_NN ._.
This_DT transaction_NN has_VBZ no_DT material_NN impact_NN on_IN reported_VBN results_NNS ._.
52_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 12_CD Debtors_NNP Group_NNP Group_NNP Company_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Due_JJ within_IN one_CD year_NN :_: Trade_NNP debtors_NNS 12_CD 732_CD Due_JJ from_IN subsidiary_NN undertakings_NNS 90_CD 88_CD Other_JJ debtors_NNS 3,982_CD 386_CD 18_CD 143_CD Prepayments_NNS and_CC accrued_VBN income_NN 2,562_CD 3,822_CD 1,519_CD 2,691_CD 6,556_CD 4,940_CD 1,627_CD 2,922_CD 13_CD Investment_NN in_IN liquid_JJ resources_NNS Group_NNP Group_NNP Company_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Negotiable_JJ securities_NNS :_: Floating_VBG rate_NN notes_NNS 24,998_CD 14,285_CD 24,998_CD 14,285_CD Certificates_NNS of_IN deposit_NN 98,000_CD 128,498_CD 98,000_CD 128,498_CD Term_NN deposits_NNS 3,696_CD 13,445_CD 2,128_CD 12,520_CD 126,694_CD 156,228_CD 125,126_CD 155,303_CD The_DT Group_NNP holds_VBZ cash_NN which_WDT is_VBZ surplus_NN to_TO current_JJ requirements_NNS ,_, but_CC which_WDT will_MD be_VB required_VBN to_TO finance_VB future_JJ operations_NNS ,_, in_IN sterling_NN in_IN interest_NN bearing_NN marketable_JJ securities_NNS as_IN described_VBN in_IN note_NN 16_CD ._.
14_CD Creditors_NNPS Group_NNP Group_NNP Company_NNP Company_NNP 2002 2001 2002 2001_CD 000 000 000 000_CD Amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN :_: Bank_NNP overdraft_NN 163_CD Trade_NNP creditors_NNS 3,999_CD 727_CD Amounts_NNS owed_VBN to_TO subsidiary_NN undertakings_NNS 1,194_CD 43,350_CD Taxation_NNP and_CC social_JJ security_NN 304_CD Other_JJ creditors_NNS 1,003_CD 534_CD Accruals_NNPS i_FW 4,710_CD 3,953_CD 48_CD 45_CD Deferred_JJ income_NN 2,547_CD 2,958_CD 12,563_CD 8,335_CD 1,242_CD 43,395_CD i_FW Includes_VBZ purchase_NN commitments_NNS of_IN 888,000_CD 2001_CD :_: 101,000_CD ._.
The_DT bank_NN overdraft_NN comprised_VBD payments_NNS to_TO suppliers_NNS and_CC other_JJ third_JJ parties_NNS which_WDT are_VBP in_IN the_DT course_NN of_IN presentation_NN ._.
15_CD Creditors_NNPS Group_NNP Group_NNP 2002 2001 000 000_CD Amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN :_: Deferred_JJ income_NN 8,580_CD 8,085_CD 53_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 16_CD Financial_NNP instruments_NNS The_DT financial_JJ instruments_NNS of_IN the_DT Group_NNP comprise_VBP cash_NN ,_, liquid_JJ resources_NNS and_CC debtors_NNS and_CC creditors_NNS arising_VBG in_IN the_DT normal_JJ course_NN of_IN business_NN ._.
The_DT Group_NNP does_VBZ not_RB trade_VB in_IN financial_JJ instruments_NNS or_CC derivatives_NNS ._.
The_DT Groups_NNS liquid_JJ resources_NNS are_VBP managed_VBN on_IN a_DT discretionary_JJ basis_NN by_IN a_DT third_JJ party_NN ._.
The_DT mandate_NN under_IN which_WDT the_DT fund_NN managers_NNS operate_VBP includes_VBZ the_DT following_VBG criteria_NNS :_: Investments_NNP only_RB in_IN freely_RB negotiable_JJ instruments_NNS or_CC deposits_NNS with_IN specified_VBN banks_NNS and_CC building_NN societies_NNS ._.
For_IN the_DT whole_JJ fund_NN ,_, limits_NNS on_IN the_DT maximum_NN exposure_NN to_TO counterparties_NNS with_IN particular_JJ minimum_JJ credit_NN ratings_NNS ,_, which_WDT ratings_NNS have_VBP been_VBN set_VBN deliberately_RB high_JJ ._.
For_IN investments_NNS in_IN particular_JJ classes_NNS of_IN instrument_NN ,_, minimum_JJ credit_NN ratings_NNS which_WDT are_VBP tighter_JJR than_IN for_IN the_DT fund_NN as_IN a_DT whole_JJ or_CC an_DT agreed_VBN counterparty_NN list_NN ._.
For_IN the_DT whole_JJ fund_NN ,_, a_DT maturity_NN profile_NN which_WDT is_VBZ tailored_VBN to_TO the_DT Groups_NNS expected_VBN cash_NN requirements_NNS as_IN investments_NNS are_VBP generally_RB held_VBN to_TO maturity_NN ._.
No_DT currency_NN exposure_NN or_CC short_JJ positions_NNS ._.
These_DT criteria_NNS are_VBP set_VBN by_IN the_DT Board_NNP and_CC are_VBP reviewed_VBN when_WRB deemed_VBN necessary_JJ ._.
The_DT principal_JJ purpose_NN of_IN the_DT Groups_NNS liquid_JJ resources_NNS is_VBZ for_IN future_JJ funding_NN and_CC hence_RB their_PRP$ safeguarding_VBG is_VBZ considered_VBN to_TO be_VB a_DT greater_JJR priority_NN than_IN the_DT actual_JJ return_NN made_VBN on_IN the_DT investments_NNS ._.
The_DT criteria_NNS for_IN fund_NN management_NN reflect_VBP this_DT ._.
The_DT Audit_NNP Committee_NNP review_NN the_DT return_NN made_VBN on_IN the_DT Groups_NNS funds_NNS against_IN benchmark_JJ market_NN returns_NNS quarterly_RB ._.
The_DT majority_NN of_IN the_DT Groups_NNS investments_NNS are_VBP short_JJ term_NN investments_NNS and_CC hence_RB exposure_NN to_TO interest_NN rate_NN changes_NNS has_VBZ been_VBN minimal_JJ ._.
Realisation_NN of_IN losses_NNS from_IN interest_NN rate_NN movements_NNS is_VBZ unlikely_JJ as_IN investments_NNS are_VBP generally_RB held_VBN to_TO maturity_NN ._.
Declines_NNS in_IN interest_NN rates_NNS over_IN time_NN will_MD ,_, however_RB ,_, reduce_VB the_DT Groups_NNS interest_NN income_NN ._.
The_DT results_NNS of_IN the_DT Group_NNP have_VBP not_RB ,_, to_TO date_NN ,_, been_VBN materially_RB impacted_VBN by_IN exchange_NN rate_NN fluctuations_NNS ._.
However_RB ,_, a_DT significant_JJ proportion_NN of_IN current_JJ and_CC future_JJ income_NN is_VBZ likely_JJ to_TO be_VB receivable_JJ in_IN United_NNP States_NNPS Dollars_NNPS which_WDT may_MD give_VB rise_VB to_TO transactional_JJ currency_NN exposures_NNS due_JJ to_TO fluctuations_NNS in_IN the_DT exchange_NN rate_NN between_IN United_NNP States_NNPS Dollars_NNPS and_CC Sterling_NNP ,_, which_WDT is_VBZ the_DT Groups_NNS functional_JJ currency_NN ._.
Where_WRB possible_JJ ,_, the_DT Group_NNP seeks_VBZ to_TO match_VB United_NNP States_NNPS Dollar_NNP income_NN with_IN United_NNP States_NNPS Dollar_NNP expenditure_NN ._.
To_TO date_VB the_DT Group_NNP has_VBZ not_RB hedged_VBN any_DT transactional_JJ currency_NN exposure_NN but_CC will_MD keep_VB such_JJ exposures_NNS under_IN review_NN and_CC where_WRB prudent_JJ and_CC appropriate_JJ may_MD enter_VB into_IN such_JJ transactions_NNS in_IN future_NN ._.
Financial_NNP Fixed_NNP rate_NN Floating_VBG rate_NN liabilities_NNS financial_JJ financial_JJ on_IN which_WDT no_DT assets_NNS i_FW assets_NNS ii_FW interest_NN is_VBZ paid_VBN Total_NNP Financial_NNP assets_NNS and_CC liabilities_NNS 000 000 000 000_CD At_IN 30_CD September_NNP 2002_CD Sterling_NNP assets_NNS liabilities_NNS 11,998_CD 114,699_CD 1,678_CD 125,019_CD United_NNP States_NNPS Dollar_NNP assets_NNS 4,755_CD 4,755_CD Other_JJ assets_NNS 1_CD 1_CD Book_NN value_NN 11,998_CD 119,455_CD 1,678_CD 129,775_CD Fair_NNP value_NN 12,000_CD 119,563_CD 1,678_CD 129,885_CD i_FW Interest_NN rates_NNS determined_VBD for_IN more_JJR than_IN one_CD year_NN ._.
ii_FW Interest_NN rates_NNS determined_VBD at_IN least_JJS once_RB a_DT year_NN ._.
54_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 16_CD Financial_NNP instruments_NNS continued_VBD Financial_JJ Fixed_JJ rate_NN Floating_VBG rate_NN liabilities_NNS financial_JJ financial_JJ on_IN which_WDT no_DT assets_NNS i_FW assets_NNS ii_FW interest_NN is_VBZ paid_VBN Total_NNP Financial_NNP assets_NNS and_CC liabilities_NNS 000 000 000 000_CD At_IN 30_CD September_NNP 2001_CD Sterling_NNP assets_NNS liabilities_NNS 8,498_CD 147,731_CD 1,346_CD 154,883_CD United_NNP States_NNPS Dollar_NNP assets_NNS 1,760_CD 1,760_CD Other_JJ assets_NNS 77_CD Book_NN value_NN 8,498_CD 149,498_CD 1,346_CD 156,650_CD Fair_NNP value_NN 8,966_CD 151,943_CD 1,346_CD 159,563_CD i_FW Interest_NN rates_NNS determined_VBD for_IN more_JJR than_IN one_CD year_NN ._.
The_DT weighted_JJ average_JJ return_NN on_IN the_DT fixed_JJ rate_NN financial_JJ assets_NNS was_VBD 3.1_CD %_NN 2001_CD :_: 6.1_CD %_NN ,_, which_WDT was_VBD fixed_VBN over_IN a_DT weighted_JJ average_JJ term_NN of_IN 1.3_CD years_NNS 2001_CD :_: 1.5_CD years_NNS ._.
The_DT returns_NNS achieved_VBN on_IN fixed_VBN and_CC floating_VBG rate_NN financial_JJ assets_NNS are_VBP determined_VBN by_IN money_NN market_NN rates_NNS prevailing_VBG at_IN the_DT date_NN a_DT transaction_NN is_VBZ entered_VBN into_IN ._.
In_IN this_DT disclosure_NN financial_JJ assets_NNS comprise_VBP liquid_JJ resources_NNS and_CC cash_NN at_IN bank_NN and_CC in_IN hand_NN ._.
Short_JJ term_NN debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN ._.
The_DT financial_JJ liabilities_NNS on_IN which_WDT no_DT interest_NN is_VBZ paid_VBN comprise_VBP payments_NNS to_TO third_JJ parties_NNS in_IN the_DT course_NN of_IN presentation_NN ._.
These_DT are_VBP payable_JJ on_IN demand_NN ._.
The_DT Directors_NNS do_VBP not_RB consider_VB the_DT deferred_JJ income_NN balances_NNS to_TO be_VB financial_JJ liabilities_NNS where_WRB monies_NNS received_VBN are_VBP non-refundable_JJ ._.
Fair_NNP value_NN of_IN marketable_JJ securities_NNS is_VBZ determined_VBN by_IN reference_NN to_TO market_NN value_NN ._.
Currency_NNP exposures_NNS At_IN the_DT year_NN end_NN the_DT Groups_NNS individual_JJ operations_NNS had_VBD the_DT following_JJ net_JJ monetary_JJ assets_NNS and_CC liabilities_NNS in_IN currencies_NNS other_JJ than_IN their_PRP$ functional_JJ currency_NN ._.
USD_NNP Sterling_NNP Other_JJ Total_NNP 000 000 000 000_CD At_IN 30_CD September_NNP 2002_CD Functional_JJ currency_NN :_: Sterling_NNP 801_CD 87_CD 714_CD United_NNP States_NNPS Dollar_NNP 90_CD 90_CD 801_CD 90_CD 87_CD 624_CD USD_NNP Sterling_NNP Other_JJ Total_NNP 000 000 000 000_CD At_IN 30_CD September_NNP 2001_CD Functional_JJ currency_NN :_: Sterling_NNP 30_CD 2_CD 28_CD United_NNP States_NNPS Dollar_NNP 88_CD 88_CD 30_CD 88_CD 2_CD 60_CD Transactions_NNS in_IN such_JJ monetary_JJ assets_NNS and_CC liabilities_NNS give_VBP rise_NN to_TO currency_NN gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
55_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 17_CD Called-up_JJ share_NN capital_NN and_CC share_NN premium_NN 2002_CD 2001_CD Authorised_VBN 000_CD 000_CD 50,000,000_CD 2001_CD :_: 50,000,000_CD ordinary_JJ shares_NNS of_IN 10p_JJ each_DT 5,000_CD 5,000_CD During_IN the_DT year_NN the_DT Directors_NNS exercised_VBN their_PRP$ powers_NNS to_TO allot_VB ordinary_JJ shares_NNS as_IN shown_VBN in_IN the_DT table_NN below_IN ._.
10p_JJ ordinary_JJ Issued_VBN Share_NN shares_NNS share_VBP capital_NN premium_NN Allotted_NNP ,_, called-up_JJ and_CC fully_RB paid_VBN Number_NNP 000_CD 000_CD At_IN 1_CD October_NNP 2001_CD 35,455,865_CD 3,546_CD 195,017_CD Issued_VBN to_TO the_DT Share_NN Incentive_NNP Plan_NNP 36,838_CD 4_CD 623_CD Exercise_NN of_IN options_NNS 251,634_CD 25_CD 755_CD Exercise_NN of_IN options_NNS i_FW 4,000_CD In_IN lieu_NN of_IN fees_NNS ii_FW 2,194_CD 37_CD To_TO Drug_NNP Royalty_NNP Corporation_NNP as_IN part_NN of_IN the_DT termination_NN of_IN the_DT royalty_NN agreement_NN iii_FW 463,818_CD 46_CD 6,102_CD At_IN 30_CD September_NNP 2002_CD 36,214,349_CD 3,621_CD 202,534_CD i_FW Exercised_VBN over_IN shares_NNS in_IN CAT_NNP Limited_NNP and_CC exchanged_VBD ._.
Issued_VBN at_IN an_DT aggregate_JJ premium_NN of_IN 5,000_CD ._.
ii_FW All_DT Non-Executive_JJ Directors_NNS elected_VBN to_TO take_VB part_NN of_IN their_PRP$ fees_NNS in_IN shares_NNS ._.
iii_FW Shares_NNS were_VBD issued_VBN at_IN a_DT price_NN of_IN 13.26_CD per_IN share_NN ,_, being_VBG the_DT average_JJ share_NN price_NN for_IN the_DT ten_CD days_NNS prior_RB to_TO 30_CD April_NNP 2002_CD ._.
At_IN 30_CD September_NNP 2002_CD options_NNS had_VBD been_VBN granted_VBN over_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN ._.
Options_NNS also_RB exist_VBP over_IN shares_NNS in_IN CAT_NNP Limited_NNP which_WDT are_VBP matched_VBN with_IN share_NN exchange_NN option_NN agreements_NNS whereby_WRB shares_NNS allotted_VBN in_IN CAT_NNP Limited_NNP on_IN exercise_NN are_VBP immediately_RB exchanged_VBN for_IN shares_NNS in_IN the_DT Company_NN ._.
The_DT tabulation_NN of_IN options_NNS below_IN reflects_VBZ the_DT effective_JJ numbers_NNS and_CC exercise_NN prices_NNS of_IN options_NNS over_IN shares_NNS in_IN the_DT Company_NN ._.
Certain_JJ options_NNS were_VBD granted_VBN in_IN one_CD scheme_NN in_IN parallel_NN with_IN options_NNS in_IN a_DT different_JJ scheme_NN under_IN arrangements_NNS whereby_WRB the_DT exercise_NN of_IN options_NNS in_IN one_CD scheme_NN would_MD cause_VB a_DT corresponding_JJ number_NN of_IN options_NNS to_TO lapse_NN in_IN the_DT other_JJ scheme_NN ._.
Where_WRB relevant_JJ ,_, pairs_NNS of_IN linked_VBN options_NNS are_VBP counted_VBN as_IN a_DT single_JJ option_NN ._.
ii_FW These_DT options_NNS were_VBD subject_JJ to_TO the_DT condition_NN as_IN stated_VBN in_IN note_NN iii_NN below_IN ._.
This_DT condition_NN had_VBD been_VBN satisfied_VBN as_IN at_IN 30_CD September_NNP 2002_CD ._.
iii_FW These_DT options_NNS are_VBP exercisable_JJ subject_NN to_TO the_DT condition_NN that_IN the_DT proportionate_NN increase_NN in_IN the_DT closing_NN price_NN of_IN shares_NNS in_IN the_DT Company_NN over_IN a_DT specified_JJ period_NN must_MD exceed_VB the_DT increase_NN in_IN the_DT Total_JJ Shareholder_NN Return_NN TSR_NNP for_IN the_DT FTSE_NNP All_NNP Share_NNP Index_NNP ._.
In_IN certain_JJ circumstances_NNS ,_, such_JJ as_IN the_DT death_NN of_IN an_DT employee_NN ,_, the_DT rules_NNS of_IN the_DT CSOP_NNP permit_VBP the_DT Directors_NNS to_TO allow_VB options_NNS which_WDT have_VBP been_VBN granted_VBN but_CC which_WDT have_VBP not_RB vested_VBN to_TO be_VB exercised_VBN provided_VBD the_DT exercise_NN takes_VBZ place_NN within_IN the_DT period_NN prescribed_VBN in_IN the_DT CSOP_NNP rules_NNS in_IN relation_NN to_TO these_DT circumstances_NNS ._.
iv_NN The_DT number_NN of_IN options_NNS which_WDT will_MD become_VB exercisable_JJ will_MD be_VB determined_VBN on_IN a_DT linear_JJ sliding_VBG scale_NN on_IN the_DT third_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN based_VBN on_IN the_DT extent_NN to_TO which_WDT the_DT TSR_NNP for_IN the_DT Company_NN exceeds_VBZ the_DT percentage_NN increase_NN in_IN the_DT TSR_NNP for_IN the_DT FTSE_NNP All_NNP Share_NNP Index_NNP by_IN an_DT amount_NN of_IN between_IN 0_CD %_NN and_CC 33_CD %_NN ._.
57_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 18_CD Profit_NN and_CC loss_NN account_NN and_CC other_JJ reserve_NN Group_NNP Group_NNP Company_NNP Profit_NNP Other_JJ Profit_NN and_CC loss_NN reserve_NN and_CC loss_NN 000 000 000_CD At_IN 1_CD October_NNP 2001_CD 55,964_CD 13,451_CD 17,725_CD Retained_VBN loss_NN profit_NN for_IN the_DT year_NN 28,207_CD 3,090_CD Premium_NNP on_IN issue_NN of_IN capital_NN in_IN subsidiary_NN 5_CD Foreign_NNP exchange_NN translation_NN 96_CD Write_VBP back_RB of_IN goodwill_NN on_IN sale_NN of_IN Denzyme_NNP ApS_NNP 229_CD At_IN 30_CD September_NNP 2002_CD 83,846_CD 13,456_CD 20,815_CD The_DT other_JJ reserve_NN represents_VBZ the_DT share_NN premium_NN account_NN of_IN CAT_NNP Limited_NNP and_CC arises_VBZ on_IN consolidation_NN from_IN the_DT application_NN of_IN merger_NN accounting_NN principles_NNS to_TO the_DT acquisition_NN of_IN that_DT company_NN ._.
The_DT cumulative_JJ amount_NN of_IN goodwill_NN written_VBN off_RP against_IN the_DT Groups_NNS reserves_NNS is_VBZ nil_JJ 2001_CD :_: 229,000_CD ._.
19_CD Reconciliation_NNP of_IN movements_NNS in_IN Group_NNP shareholders_NNS funds_NNS 2002 2001 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 28,207_CD 11,771_CD Other_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 325_CD 1_CD 27,882_CD 11,770_CD New_NNP shares_NNS issued_VBD 7,597_CD 15,380_CD Net_JJ decrease_NN increase_NN in_IN shareholders_NNS funds_NNS 20,285_CD 3,610_CD Opening_NN shareholders_NNS funds_NNS 156,050_CD 152,440_CD Closing_NN shareholders_NNS funds_NNS 135,765_CD 156,050_CD 20_CD Reconciliation_NNP of_IN operating_VBG loss_NN to_TO operating_VBG cash_NN flows_NNS 2002 2001 2000 000_CD 000_CD 000_CD Operating_NN loss_NN 38,150_CD 21,066_CD 13,933_CD Depreciation_NN charge_NN 2,617_CD 2,146_CD 1,808_CD Amortisation_NNP of_IN intangible_JJ assets_NNS 882 373 374_CD Loss_NN profit_NN on_IN disposal_NN of_IN fixed_JJ assets_NNS 1_CD 5_CD Shares_NNS issued_VBN to_TO buy_VB out_RP DRC_NNP royalty_NN agreement_NN 6,149_CD Increase_VBP in_IN debtors_NNS 158_CD 515_CD 1,159_CD Increase_VBP decrease_NN in_IN creditors_NNS 1,852_CD 89_CD 9,306_CD Net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS 26,808_CD 19,150_CD 3,609_CD 58_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 21_CD Analysis_NN of_IN cash_NN flows_NNS 2002 2001 2000 000_CD 000_CD 000_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN Interest_NN received_VBD 7,558_CD 8,322_CD 4,245_CD Net_JJ cash_NN inflow_NN 7,558_CD 8,322_CD 4,245_CD Taxation_NNP Research_NNP and_CC development_NN tax_NN credit_NN received_VBN 920_CD Net_JJ cash_NN inflow_NN 920_CD Capital_NNP expenditure_NN and_CC financial_JJ investment_NN Purchase_NN of_IN intangible_JJ assets_NNS 2,067_CD Purchase_NN of_IN tangible_JJ fixed_JJ assets_NNS 7,894_CD 3,485_CD 1,018_CD Proceeds_NNS from_IN the_DT sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 444_CD Net_JJ cash_NN outflow_NN 9,961_CD 3,481_CD 974_CD Management_NN of_IN liquid_JJ resources_NNS Decrease_NN increase_NN in_IN term_NN deposits_NNS 9,749_CD 10,762_CD 23,980_CD Net_JJ sale_NN purchase_NN of_IN securities_NNS 19,785_CD 10,488_CD 109,749_CD Net_JJ cash_NN inflow_NN outflow_NN 29,534_CD 274_CD 133,729_CD Financing_NN Issue_NN of_IN ordinary_JJ share_NN capital_NN 1,448_CD 15,380_CD 132,302_CD Capital_NN elements_NNS of_IN finance_NN lease_NN rental_JJ payments_NNS 9_CD Net_JJ cash_NN inflow_NN 1,448_CD 15,380_CD 132,293_CD Liquid_NN resources_NNS comprise_VBP current_JJ asset_NN investments_NNS in_IN negotiable_JJ securities_NNS and_CC cash_NN deposits_NNS ._.
22_CD Analysis_NN and_CC reconciliation_NN of_IN net_JJ funds_NNS 1_CD October_NNP Exchange_NNP 30_CD September_NNP 2001_CD Cash_NN flow_NN movement_NN 2002 000 000 000_CD 000_CD Cash_NN at_IN bank_NN 585_CD 2,528_CD 32_CD 3,081_CD Overdrafts_NNPS 163_CD 163_CD 2,691_CD 32_CD Liquid_NN resources_NNS 156,228_CD 29,534_CD 126,694_CD Net_JJ funds_NNS 156,650_CD 26,843_CD 32_CD 129,775_CD 59_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 22_CD Analysis_NN and_CC reconciliation_NN of_IN net_JJ funds_NNS continued_VBD 2002 2001 2000 000_CD 000_CD 000_CD Increase_VBP decrease_NN in_IN cash_NN in_IN the_DT year_NN 2,691_CD 1,345_CD 1,774_CD Decrease_NN increase_NN in_IN liquid_JJ resources_NNS 29,534_CD 274_CD 133,729_CD Decrease_NN in_IN lease_NN financing_NN 9_CD Change_NNP in_IN net_JJ funds_NNS resulting_VBG from_IN cash_NN flows_NNS 26,843_CD 1,071_CD 131,964_CD Exchange_NNP movement_NN 32_CD 2_CD Movement_NNP in_IN net_JJ funds_NNS in_IN year_NN 26,875_CD 1,071_CD 131,966_CD Net_JJ funds_NNS at_IN 1_CD October_NNP 2001_CD 156,650_CD 155,579_CD 23,613_CD Net_JJ funds_NNS at_IN 30_CD September_NNP 2002_CD 129,775_CD 156,650_CD 155,579_CD 23_CD Financial_NNP commitments_NNS Capital_NNP commitments_NNS of_IN the_DT Group_NNP were_VBD as_IN follows_VBZ :_: Group_NNP Group_NNP 2002 2001 000 000_CD Contracted_VBN but_CC not_RB provided_VBN for_IN 515_CD 827_CD Since_IN the_DT end_NN of_IN the_DT 2002_CD financial_JJ year_NN the_DT Group_NNP has_VBZ established_VBN a_DT finance_NN leasing_VBG facility_NN ._.
Furniture_NNP and_CC equipment_NN with_IN a_DT cost_NN of_IN 504,000_CD have_VBP been_VBN financed_VBN under_IN this_DT facility_NN which_WDT is_VBZ repayable_JJ over_IN four_CD years_NNS ._.
In_IN the_DT next_JJ year_NN the_DT Group_NNP has_VBZ operating_VBG lease_NN commitments_NNS as_IN follows_VBZ ,_, categorised_VBN by_IN period_NN to_TO expiry_VB ._.
Land_NNP and_CC Land_NNP and_CC buildings_NNS Other_JJ buildings_NNS Other_JJ 2002 2002 2001 2001_CD 000 000 000 000_CD Expiry_NNP date_NN :_: within_IN one_CD year_NN 2_CD between_IN two_CD and_CC five_CD years_NNS 48_CD 1_CD after_IN five_CD years_NNS 1,801_CD 836_CD The_DT Company_NN had_VBD no_DT capital_NN or_CC operating_NN lease_NN commitments_NNS ._.
24_CD Pension_NNP arrangements_NNS The_DT Group_NNP operates_VBZ a_DT group_NN personal_JJ pension_NN plan_NN which_WDT is_VBZ a_DT defined_VBN contribution_NN plan_NN ._.
60_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 25_CD Related_VBN party_NN transactions_NNS During_IN the_DT 2000_CD financial_JJ year_NN CAT_NNP Limited_NNP paid_VBD a_DT fee_NN of_IN US$_$ 1.3_CD million_CD to_TO Prudential_NNP Vector_NNP Healthcare_NNP Group_NNP Prudential_NNP Vector_NNP under_IN an_DT arrangement_NN whereby_WRB Prudential_NNP Vector_NNP agreed_VBD to_TO provide_VB certain_JJ financial_JJ advisory_JJ services_NNS ._.
The_DT arrangement_NN was_VBD subsequently_RB terminated_VBN although_IN Prudential_NNP Vector_NNP were_VBD ,_, in_IN certain_JJ circumstances_NNS ,_, entitled_VBN to_TO a_DT further_JJ fee_NN in_IN respect_NN of_IN further_JJ transactions_NNS entered_VBD into_IN by_IN CAT_NNP Limited_NNP in_IN the_DT period_NN up_IN to_TO February_NNP 2001_CD ._.
No_DT such_JJ further_JJ transactions_NNS or_CC payments_NNS have_VBP taken_VBN place_NN ._.
J_NNP L_NNP Foght_NNP was_VBD a_DT managing_NN director_NN of_IN Prudential_NNP Vector_NNP at_IN the_DT time_NN the_DT arrangement_NN was_VBD entered_VBN into_IN and_CC the_DT payment_NN made_VBN and_CC is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN the_DT Company_NN ._.
The_DT Board_NNP of_IN Directors_NNS has_VBZ determined_VBN that_IN this_DT transaction_NN did_VBD not_RB interfere_VB with_IN Dr_NNP Foghts_NNP exercise_NN of_IN independent_JJ judgement_NN and_CC accordingly_RB has_VBZ determined_VBN that_IN he_PRP is_VBZ an_DT independent_JJ Director_NNP under_IN the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP and_CC that_IN it_PRP is_VBZ in_IN the_DT best_JJS interests_NNS of_IN the_DT Company_NN that_IN he_PRP continue_VBP to_TO serve_VB on_IN the_DT Audit_NNP Committee_NNP ._.
In_IN accordance_NN with_IN FRS_NNP 8_CD ,_, Related_NNP Party_NNP Disclosures_NNS ,_, the_DT Group_NNP does_VBZ not_RB disclose_VB transactions_NNS or_CC balances_NNS between_IN group_NN entities_NNS which_WDT are_VBP wholly_RB eliminated_VBN on_IN consolidation_NN ._.
26_CD Litigation_NN As_IN previously_RB reported_VBN ,_, CATs_NNS patent_NN infringement_NN action_NN against_IN MorphoSys_NNP relating_VBG to_TO the_DT European_JJ Winter_NNP II_NNP and_CC McCafferty_NNP patents_NNS in_IN Munich_NNP is_VBZ currently_RB stayed_VBN pending_VBG the_DT outcome_NN of_IN appeal_NN proceedings_NNS at_IN the_DT European_JJ Patent_NNP Office_NNP ._.
In_IN March_NNP 2002_CD the_DT District_NNP Court_NNP in_IN Washington_NNP DC_NNP issued_VBD a_DT formal_JJ ruling_NN that_WDT MorphoSys_NNPS does_VBZ not_RB infringe_VB CATs_NNS US_NNP Griffiths_NNP patent_NN ._.
The_DT decision_NN was_VBD based_VBN on_IN the_DT method_NN by_IN which_WDT MorphoSys_NNP library_NN is_VBZ derived_VBN ._.
CAT_NNP has_VBZ appealed_VBN this_DT decision_NN ._.
The_DT appeal_NN will_MD be_VB limited_VBN to_TO the_DT issue_NN as_IN to_TO whether_IN MorphoSys_NNP infringes_VBZ the_DT Griffiths_NNP patent_NN ._.
A_DT hearing_NN date_NN has_VBZ not_RB yet_RB been_VBN set_VBN but_CC it_PRP is_VBZ anticipated_VBN that_IN the_DT hearing_NN will_MD take_VB place_NN in_IN mid_JJ 2003_CD ._.
May_NNP 2003_CD has_VBZ been_VBN proposed_VBN as_IN the_DT trial_NN date_NN for_IN the_DT two_CD legal_JJ actions_NNS in_IN the_DT District_NNP Court_NNP in_IN Washington_NNP DC_NNP in_IN which_WDT CAT_NNP claims_VBZ that_IN MorphoSys_NNP infringes_VBZ its_PRP$ Winter_NNP II_NNP patent_NN and_CC two_CD of_IN the_DT Winter_NNP Lerner_NNP Huse_NNP patents_NNS ._.
The_DT preliminary_JJ Markman_NNP Hearings_NNS on_IN these_DT cases_NNS were_VBD postponed_VBN ._.
A_DT new_JJ date_NN for_IN these_DT hearings_NNS has_VBZ yet_RB to_TO be_VB set_VBN by_IN the_DT Court_NNP ._.
A_DT trial_NN date_NN of_IN 17_CD February_NNP 2003_CD has_VBZ been_VBN proposed_VBN for_IN the_DT legal_JJ action_NN brought_VBN by_IN MorphoSys_NNP in_IN respect_NN of_IN CATs_NNPS US_NNP McCafferty_NNP patent_NN ._.
The_DT preliminary_JJ Markman_NNP Hearing_NNP on_IN this_DT case_NN was_VBD postponed_VBN ._.
A_DT new_JJ date_NN for_IN this_DT hearing_NN has_VBZ yet_RB to_TO be_VB set_VBN by_IN the_DT Court_NNP ._.
As_IN previously_RB reported_VBN ,_, in_IN 2000_CD Crucell_NNP issued_VBD writs_NNS against_IN the_DT Medical_NNP Research_NNP Council_NNP MRC_NNP ,_, Scripps_NNP and_CC Stratagene_NNP in_IN a_DT Dutch_JJ national_JJ court_NN ,_, seeking_VBG a_DT declaration_NN that_IN the_DT Winter_NNP II_NNP patent_NN was_VBD invalid_JJ or_CC that_IN Crucell_NNP did_VBD not_RB infringe_VB the_DT claims_NNS of_IN the_DT patent_NN ._.
A_DT separate_JJ writ_NN against_IN MRC_NNP sought_VBD a_DT similar_JJ declaration_NN in_IN respect_NN of_IN the_DT McCafferty_NNP patent_NN ._.
Pursuant_JJ to_TO its_PRP$ agreements_NNS with_IN the_DT defendants_NNS ,_, CAT_NNP is_VBZ responsible_JJ for_IN the_DT defense_NN of_IN these_DT proceedings_NNS ._.
The_DT Court_NNP has_VBZ declined_VBN jurisdiction_NN for_IN Crucells_NNP non_NN infringement_NN claims_NNS and_CC assumed_VBD jurisdiction_NN only_RB on_IN the_DT invalidity_NN claims_VBZ any_DT decision_NN will_MD only_RB cover_VB Holland_NNP ._.
The_DT Courts_NNS ruling_VBG to_TO decline_VB jurisdiction_NN in_IN the_DT Winter_NNP II_NNP case_NN is_VBZ currently_RB under_IN appeal_NN by_IN Crucell_NNP ._.
CAT_NNP intends_VBZ to_TO defend_VB these_DT proceedings_NNS vigorously_RB and_CC does_VBZ not_RB believe_VB there_EX is_VBZ merit_NN in_IN these_DT claims_NNS ._.
Whatever_WDT the_DT outcome_NN of_IN the_DT above_JJ litigation_NN activity_NN ,_, CAT_NNP believes_VBZ that_IN its_PRP$ ability_NN to_TO operate_VB its_PRP$ own_JJ technology_NN will_MD not_RB be_VB materially_RB and_CC adversely_RB affected_VBN ._.
As_IN previously_RB reported_VBN ,_, following_VBG certain_JJ share_NN issues_NNS by_IN Cambridge_NNP Antibody_NNP Technology_NNP Limited_NNP ,_, Continental_NNP Venture_NNP Capital_NNP Limited_NNP CVC_NNP issued_VBD proceedings_NNS in_IN the_DT State_NN of_IN New_NNP York_NNP claiming_VBG that_IN it_PRP is_VBZ entitled_VBN to_TO anti-dilution_JJ shares_NNS equivalent_JJ to_TO 25,790_CD ordinary_JJ shares_NNS of_IN 10p_JJ each_DT ._.
If_IN CVC_NNP succeeds_VBZ then_RB the_DT Directors_NNS would_MD be_VB obliged_VBN to_TO issue_VB anti-dilution_JJ shares_NNS to_TO all_DT similarly_RB situated_VBN participants_NNS approximately_RB 763,000_CD ordinary_JJ shares_NNS of_IN 10p_JJ each_DT ._.
Both_DT parties_NNS issued_VBD cross_JJ motions_NNS for_IN summary_NN judgement_NN which_WDT were_VBD denied_VBN in_IN May_NNP 2000_CD ._.
There_EX has_VBZ been_VBN no_DT change_NN in_IN the_DT status_NN of_IN proceedings_NNS during_IN the_DT year_NN and_CC the_DT Directors_NNS continue_VBP to_TO believe_VB ,_, on_IN the_DT basis_NN of_IN legal_JJ advice_NN they_PRP have_VBP received_VBN ,_, that_IN the_DT proceedings_NNS have_VBP no_DT merit_NN ._.
61_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP Summary_NNP of_IN Significant_NNP Differences_NNS Between_IN UK_NNP GAAP_NNP Followed_VBN by_IN the_DT Group_NNP and_CC US_NNP GAAP_NNP The_NNP Groups_NNS consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ,_, which_WDT differs_VBZ in_IN certain_JJ significant_JJ respects_NNS from_IN accounting_VBG principles_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP US_NNP GAAP_NNP ._.
The_DT following_NN is_VBZ a_DT summary_NN of_IN significant_JJ adjustments_NNS to_TO net_JJ loss_NN and_CC shareholders_NNS funds_NNS required_VBN when_WRB reconciling_VBG such_JJ amounts_NNS recorded_VBN in_IN the_DT financial_JJ statements_NNS to_TO the_DT corresponding_JJ amounts_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP ,_, considering_VBG the_DT significant_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ._.
Reconciliation_NNP of_IN net_JJ loss_NN from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP 2002 2001 2000_CD Notes_NNP 000 000 000_CD Net_JJ loss_NN as_IN reported_VBN under_IN UK_NNP GAAP_NNP 28,207_CD 11,771_CD 8,289_CD Adjustments_NNS for_IN :_: Compensation_NNP costs_NNS under_IN variable_JJ plan_NN accounting_NN for_IN stock_NN options_NNS a_DT 3,703_CD 7,804_CD 8,223_CD Acquisition_NNP of_IN Aptein_NNP Inc._NNP b_NN 16_CD 16_CD 16_CD Revenue_NN recognition_NN c_NN 422 422 111_CD Accounting_NN for_IN National_NNP Insurance_NNP on_IN share_NN options_NNS d_LS 248 194 523_CD Reclassification_NN of_IN share_NN issue_NN expenses_NNS e_LS 202_CD 1,237_CD Profit_NN on_IN sale_NN of_IN Denzyme_NNP ApS_NNP f_SYM 229_CD Termination_NN of_IN DRC_NNP royalty_NN agreement_NN g_NN 723_CD Foreign_NNP exchange_NN difference_NN h_VBP 491_CD Net_JJ loss_NN as_IN reported_VBN under_IN US_NNP GAAP_NNP 31,291_CD 19,565_CD 17,131_CD Loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP would_MD compute_VB loss_NN per_IN share_NN under_IN Statement_NNP of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
128_CD ,_, basic_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN is_VBZ computed_JJ using_VBG the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS of_IN common_JJ stock_NN outstanding_JJ during_IN the_DT period_NN ._.
Diluted_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN for_IN CAT_NNP is_VBZ the_DT same_JJ as_IN basic_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN as_IN the_DT effects_NNS of_IN the_DT Companys_NNPS potential_JJ ordinary_JJ share_NN equivalents_NNS are_VBP antidilutive_JJ ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT basis_NN of_IN calculation_NN is_VBZ the_DT same_JJ ._.
However_RB ,_, since_IN different_JJ net_JJ losses_NNS are_VBP produced_VBN under_IN US_NNP GAAP_NNP and_CC UK_NNP GAAP_NNP the_DT net_JJ loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP is_VBZ presented_VBN below_IN :_: 2002 2001 2000_CD Basic_JJ and_CC diluted_JJ net_JJ loss_NN per_IN ordinary_JJ share_NN pence_NN 87.3_CD 55.4_CD 56.8_CD Shares_NNS used_VBN in_IN computing_VBG net_JJ loss_NN per_IN ordinary_JJ share_NN number_NN 35,828,446_CD 35,313,260_CD 30,179,818_CD Antidilutive_JJ securities_NNS ,_, not_RB included_VBN above_IN number_NN 867,316_CD 1,077,800_CD 1,548,764_CD Antidilutive_JJ securities_NNS represent_VBP stock_NN options_NNS outstanding_JJ which_WDT have_VBP not_RB been_VBN included_VBN in_IN the_DT calculation_NN of_IN loss_NN per_IN ordinary_JJ share_NN as_IN the_DT impact_NN of_IN including_VBG such_JJ shares_NNS in_IN the_DT calculation_NN of_IN loss_NN per_IN share_NN would_MD be_VB antidilutive_JJ ._.
Reconciliation_NNP of_IN shareholders_NNS funds_NNS from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP 2002 2001 2000_CD Notes_NNP 000 000 000_CD Shareholders_NNS funds_NNS as_IN reported_VBN under_IN UK_NNP GAAP_NNP 135,765_CD 156,050_CD 152,440_CD Acquisition_NNP of_IN Aptein_NNP Inc._NNP b_NN 127 143 159_CD Revenue_NN recognition_NN c_NN 2,375_CD 2,797_CD 1,768_CD Accounting_NN for_IN National_NNP Insurance_NNP on_IN stock_NN options_NNS d_LS 81 329 523_CD Shareholders_NNS funds_NNS as_IN reported_VBN under_IN US_NNP GAAP_NNP 133,598_CD 153,725_CD 151,354_CD 62_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD Reconciliation_NNP of_IN movement_NN in_IN shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP Share_NNP Total_NNP shareholders_NNS Number_NNP of_IN shares_NNS Share_NN capital_NN premium_NN account_NN Other_JJ reserve_NN Accumulated_VBN loss_NN equity_NN 000 000 000 000_CD 000_CD 000_CD Balance_NN ,_, 30_CD September_NNP 2000_CD 34,770,438_CD 3,477_CD 187,274_CD 13,492_CD 52,889_CD 151,354_CD Shares_NNS issued_VBN 685,427_CD 69_CD 14,062_CD 14,131_CD Compensation_NNP costs_NNS for_IN stock_NN options_NNS 7,804_CD 7,804_CD Foreign_JJ exchange_NN translation_NN 11_CD Net_JJ loss_NN for_IN the_DT year_NN under_IN US_NNP GAAP_NNP 19,565_CD 19,565_CD Total_JJ comprehensive_JJ income_NN 19,564_CD Balance_NNP ,_, 30_CD September_NNP 2001_CD 35,455,865_CD 3,546_CD 209,140_CD 13,492_CD 72,453_CD 153,725_CD Shares_NNS issued_VBN 758,484_CD 75_CD 6,794_CD 5_CD 6,874_CD Compensation_NNP costs_NNS for_IN stock_NN options_NNS 3,703_CD 3,703_CD Foreign_JJ exchange_NN translation_NN 587_CD 587_CD Net_JJ loss_NN for_IN the_DT year_NN under_IN US_NNP GAAP_NNP 31,291_CD 31,291_CD Total_JJ comprehensive_JJ income_NN 30,704_CD Balance_NNP ,_, 30_CD September_NNP 2002_CD 36,214,349_CD 3,621_CD 219,637_CD 13,497_CD 103,157_CD 133,598_CD Total_JJ accumulated_VBN other_JJ comprehensive_JJ income_NN foreign_JJ currency_NN translations_NNS at_IN 30_CD September_NNP 2001_CD was_VBD 1,000_CD and_CC at_IN 30_CD September_NNP 2002_CD was_VBD 588,000_CD ._.
a_DT Compensation_NNP costs_NNS under_IN variable_JJ plan_NN accounting_NN for_IN stock_NN options_NNS ._.
CAT_NNP has_VBZ granted_VBN stock_NN options_NNS to_TO employees_NNS that_WDT will_MD vest_NN upon_IN the_DT attainment_NN of_IN certain_JJ targets_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, there_EX is_VBZ no_DT accounting_NN for_IN the_DT cost_NN of_IN these_DT grants_NNS after_IN the_DT initial_JJ grant_NN date_NN ._.
Under_IN US_NNP GAAP_NNP ,_, Accounting_NNP Principles_NNP Board_NNP APB_NNP Opinion_NNP 25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS ,_, the_DT Company_NN is_VBZ required_VBN to_TO follow_VB variable_JJ plan_NN accounting_NN for_IN these_DT grants_NNS ._.
The_DT nature_NN of_IN conditions_NNS attached_VBN to_TO the_DT stock_NN options_NNS awards_NNS mean_VBP that_IN management_NN can_MD not_RB make_VB a_DT reasonable_JJ estimate_NN of_IN the_DT number_NN of_IN shares_NNS that_WDT will_MD be_VB eventually_RB issued_VBN because_IN the_DT Company_NN can_MD not_RB control_VB the_DT achievements_NNS of_IN the_DT conditions_NNS ._.
As_IN a_DT consequence_NN ,_, the_DT compensation_NN expense_NN for_IN the_DT stock_NN awards_NNS is_VBZ recorded_VBN when_WRB and_CC only_RB when_WRB the_DT options_NNS vest_NN when_WRB the_DT target_NN is_VBZ achieved_VBN ,_, based_VBN on_IN the_DT difference_NN between_IN the_DT exercise_NN price_NN and_CC market_NN value_NN at_IN that_DT date_NN ._.
The_DT targets_NNS were_VBD first_RB achieved_VBN in_IN the_DT year_NN ended_VBD 30_CD September_NNP 2000_CD ._.
There_EX is_VBZ no_DT tax_NN effect_NN related_VBN to_TO the_DT adjustments_NNS in_IN respect_NN of_IN stock_NN options_NNS ._.
b_NN Accounting_NN for_IN the_DT acquisition_NN of_IN Aptein_NNP Inc._NNP ._.
The_DT Company_NN acquired_VBD Aptein_NNP Inc._NNP ._.
Aptein_NNP in_IN July_NNP 1998_CD for_IN consideration_NN payable_JJ partly_RB on_IN completion_NN ,_, the_DT remainder_NN being_VBG deferred_VBN ,_, payable_JJ subject_NN to_TO the_DT achievement_NN of_IN certain_JJ conditions_NNS ._.
Aptein_NNP was_VBD acquired_VBN for_IN its_PRP$ patent_NN portfolio_NN ,_, which_WDT comprised_VBD its_PRP$ only_JJ material_NN asset_NN ._.
The_DT value_NN of_IN purchase_NN consideration_NN therefore_RB had_VBD a_DT corresponding_JJ impact_NN on_IN the_DT fair_JJ value_NN ascribed_VBD to_TO the_DT patents_NNS ,_, which_WDT are_VBP shown_VBN in_IN the_DT balance_NN sheet_NN as_IN an_DT intangible_JJ asset_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, in_IN accordance_NN with_IN FRS_NNP 7_CD Fair_NNP Values_NNP in_IN Acquisition_NNP Accounting_NNP ,_, the_DT fair_JJ value_NN of_IN the_DT deferred_JJ consideration_NN was_VBD recognized_VBN immediately_RB and_CC the_DT fair_JJ value_NN of_IN the_DT contingent_JJ consideration_NN which_WDT was_VBD payable_JJ by_IN the_DT issue_NN of_IN shares_NNS in_IN the_DT Company_NN was_VBD reported_VBN as_IN part_NN of_IN shareholders_NNS funds_NNS as_IN shares_NNS to_TO be_VB issued_VBN ._.
The_DT difference_NN between_IN the_DT initial_JJ investment_NN of_IN the_DT contingent_JJ consideration_NN and_CC the_DT actual_JJ amount_NN was_VBD recorded_VBN as_IN an_DT adjustment_NN to_TO the_DT purchase_NN price_NN in_IN June_NNP 1999_CD ,_, when_WRB paid_VBN ._.
At_IN this_DT time_NN a_DT corresponding_JJ adjustment_NN to_TO the_DT value_NN of_IN the_DT intangible_JJ asset_NN was_VBD also_RB recognized_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, APB_NNP Opinion_NNP 16_CD ,_, Accounting_NNP for_IN Business_NNP Combinations_NNPS ,_, contingent_JJ consideration_NN is_VBZ not_RB recorded_VBN until_IN such_JJ time_NN as_IN the_DT contingency_NN is_VBZ resolved_VBN ._.
Accordingly_RB ,_, prior_RB to_TO the_DT actual_JJ payment_NN of_IN the_DT contingent_JJ consideration_NN the_DT recorded_VBN value_NN of_IN the_DT intangible_JJ asset_NN under_IN US_NNP GAAP_NNP was_VBD lower_JJR than_IN under_IN UK_NNP GAAP_NNP ,_, resulting_VBG in_IN a_DT lower_JJR amortisation_NN charge_NN ._.
On_IN payment_NN of_IN the_DT contingent_JJ consideration_NN ,_, the_DT amortisation_NN charge_NN under_IN US_NNP GAAP_NNP increased_VBD above_IN UK_NNP GAAP_NNP as_IN a_DT consequence_NN of_IN the_DT higher_JJR unamortised_JJ cost_NN ._.
63_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD c_NN Revenue_NN recognition_NN ._.
The_DT nature_NN of_IN the_DT Groups_NNS principal_JJ revenue_NN streams_NNS and_CC the_DT Groups_NNS accounting_VBG policy_NN for_IN revenue_NN recognition_NN under_IN UK_NNP GAAP_NNP are_VBP as_IN detailed_VBN in_IN note_NN 1_CD ._.
For_IN US_NNP GAAP_NNP purposes_NNS ,_, the_DT Company_NN has_VBZ adopted_VBN ,_, for_IN all_DT periods_NNS ,_, Staff_NNP Accounting_NNP Bulletin_NNP 101_CD SAB101_CD ,_, Revenue_NN Recognition_NN in_IN Financial_NNP Statements_NNP ,_, which_WDT was_VBD issued_VBN by_IN the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP SEC_NNP in_IN December_NNP 1999_CD ._.
The_DT treatment_NN of_IN revenues_NNS under_IN US_NNP GAAP_NNP is_VBZ equivalent_JJ to_TO that_DT under_IN UK_NNP GAAP_NNP except_IN as_IN follows_VBZ :_: Under_IN US_NNP GAAP_NNP ,_, where_WRB licensing_NN arrangements_NNS are_VBP accompanied_VBN by_IN an_DT equity_NN subscription_NN agreement_NN ,_, the_DT series_NN of_IN transactions_NNS have_VBP been_VBN accounted_VBN for_IN as_IN a_DT multiple_JJ elements_NNS arrangement_NN ._.
Accordingly_RB the_DT aggregate_JJ consideration_NN has_VBZ been_VBN allocated_VBN to_TO the_DT two_CD elements_NNS of_IN the_DT arrangement_NN as_IN follows_VBZ ._.
The_DT fair_JJ value_NN of_IN the_DT equity_NN subscription_NN is_VBZ calculated_VBN as_IN being_VBG the_DT aggregate_JJ number_NN of_IN shares_NNS issued_VBN at_IN the_DT average_NN of_IN the_DT opening_NN and_CC closing_NN share_NN prices_NNS on_IN the_DT date_NN of_IN issue_NN ._.
Any_DT deficit_NN or_CC premium_NN arising_VBG from_IN the_DT aggregate_JJ value_NN of_IN the_DT share_NN subscription_NN over_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS is_VBZ recorded_VBN as_IN an_DT adjustment_NN to_TO licence_NN revenues_NNS ._.
No_DT such_JJ reallocation_NN is_VBZ made_VBN under_IN UK_NNP GAAP_NNP ._.
During_IN the_DT years_NNS ended_VBN 30_CD September_NNP 2002_CD and_CC 2001_CD licence_NN revenues_NNS under_IN US_NNP GAAP_NNP were_VBD therefore_RB 422,000_CD higher_JJR ._.
For_IN the_DT year_NN ended_VBD 30_CD September_NNP 2000_CD licence_NN revenues_NNS under_IN US_NNP GAAP_NNP were_VBD 111,000_CD higher_JJR ._.
d_LS Accounting_NN for_IN National_NNP Insurance_NNP on_IN share_NN options_NNS ._.
Under_IN UK_NNP GAAP_NNP the_DT Company_NN has_VBZ accounted_VBN for_IN a_DT potential_JJ liability_NN to_TO National_NNP Insurance_NNP on_IN employee_NN share_NN options_NNS ._.
The_DT provision_NN is_VBZ being_VBG made_VBN systematically_RB by_IN reference_NN to_TO the_DT market_NN value_NN of_IN shares_NNS at_IN the_DT balance_NN sheet_NN dates_NNS over_IN the_DT period_NN from_IN the_DT date_NN of_IN grant_NN to_TO the_DT end_NN of_IN the_DT relevant_JJ performance_NN period_NN and_CC from_IN that_DT date_NN to_TO the_DT date_NN of_IN actual_JJ exercise_NN the_DT provision_NN will_MD be_VB adjusted_VBN by_IN reference_NN to_TO changes_NNS in_IN market_NN value_NN ._.
The_DT provision_NN at_IN 30_CD September_NNP 2002_CD was_VBD 81,000_CD and_CC the_DT net_JJ credit_NN for_IN the_DT year_NN then_RB ended_VBD amounted_VBD to_TO 248,000_CD ._.
Under_IN US_NNP GAAP_NNP ,_, Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP Issue_NNP 00-16_CD Recognition_NNP and_CC Measurement_NNP of_IN Employer_NNP Payroll_NNP Taxes_NNS on_IN Employee_NNP Stock-Based_NNP Compensation_NNP ,_, no_DT liability_NN to_TO National_NNP Insurance_NNP is_VBZ recognized_VBN until_IN such_JJ time_NN as_IN the_DT share_NN option_NN is_VBZ exercised_VBN since_IN this_DT is_VBZ when_WRB the_DT liability_NN crystallises_NNS ._.
Under_IN the_DT agreement_NN with_IN DRC_NNP the_DT Group_NNP received_VBD an_DT amount_NN of_IN 1.5_CD million_CD in_IN 1994_CD in_IN exchange_NN for_IN rights_NNS to_TO a_DT percentage_NN of_IN the_DT cash_NN receivable_NN in_IN respect_NN of_IN certain_JJ revenues_NNS and_CC certain_JJ equity_NN issues_NNS where_WRB these_DT equity_NN issues_NNS form_VBP part_NN of_IN a_DT commercial_JJ collaboration_NN ._.
Under_IN UK_NNP GAAP_NNP amounts_VBZ paid_VBN to_TO DRC_NNP as_IN a_DT result_NN of_IN an_DT equity_NN subscription_NN are_VBP accounted_VBN for_IN as_IN a_DT share_NN issue_NN expense_NN since_IN they_PRP are_VBP considered_VBN to_TO be_VB directly_RB related_VBN to_TO the_DT share_NN issue_NN ._.
Under_IN US_NNP GAAP_NNP these_DT amounts_NNS are_VBP not_RB considered_VBN to_TO be_VB a_DT share_NN issue_NN cost_NN since_IN DRC_NNP are_VBP not_RB providing_VBG any_DT services_NNS in_IN connection_NN with_IN the_DT equity_NN issue_NN ._.
Accordingly_RB ,_, such_JJ amounts_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN for_IN the_DT year_NN under_IN US_NNP GAAP_NNP ._.
f_LS Profit_NN on_IN sale_NN of_IN Denzyme_NNP ApS_NNP ._.
Goodwill_NN of_IN 229,000_CD arose_VBD on_IN the_DT purchase_NN of_IN Denzume_NNP ApS_NNP in_IN June_NNP 1996_CD ._.
In_IN accordance_NN with_IN the_DT UK_NNP accounting_NN standard_NN then_RB in_IN force_NN Statement_NN of_IN Standard_NNP Accounting_NNP Practice_NNP 22_CD this_DT goodwill_NN was_VBD written_VBN off_RP to_TO reserves_NNS ._.
Under_IN US_NNP GAAP_NNP the_DT goodwill_NN was_VBD expensed_VBN in_IN the_DT income_NN statement_NN ._.
The_DT Company_NN sold_VBD Denzyme_NNP ApS_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN ,_, in_IN November_NNP 2001_CD ._.
Under_IN UK_NNP GAAP_NNP the_DT calculated_JJ profit_NN on_IN disposal_NN takes_VBZ account_NN of_IN the_DT goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS resulting_VBG in_IN a_DT profit_NN on_IN disposal_NN of_IN 2,000_CD ._.
Under_IN US_NNP GAAP_NNP there_EX is_VBZ no_DT requirement_NN to_TO write_VB back_RP the_DT goodwill_NN as_IN it_PRP has_VBZ already_RB been_VBN charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Therefore_RB under_IN US_NNP GAAP_NNP the_DT profit_NN on_IN disposal_NN of_IN Denzyme_NNP ApS_NNP is_VBZ 231,000_CD ._.
g_NN Termination_NN of_IN DRC_NNP royalty_NN agreement_NN ._.
Under_IN an_DT agreement_NN with_IN DRC_NNP the_DT Group_NNP received_VBD a_DT payment_NN of_IN 1.5_CD million_CD in_IN 1994_CD in_IN return_NN for_IN rights_NNS to_TO a_DT percentage_NN of_IN revenues_NNS and_CC certain_JJ other_JJ payments_NNS received_VBN by_IN the_DT Group_NNP over_IN a_DT period_NN terminating_VBG in_IN 2009_CD ._.
On_IN 2_CD May_NNP 2002_CD the_DT Group_NNP bought_VBD out_RP this_DT obligation_NN to_TO DRC_NNP for_IN 6.1_CD million_CD C$_$ 14_CD million_CD with_IN the_DT issue_NN of_IN 463,818_CD CAT_NNP shares_NNS to_TO DRC_NNP ._.
Under_IN UK_NNP GAAP_NNP the_DT share_NN price_NN applied_VBD to_TO this_DT transaction_NN defined_VBN in_IN the_DT contract_NN ,_, was_VBD the_DT volume_NN weighted_VBN average_JJ closing_NN CAT_NNP share_NN price_NN over_IN the_DT ten_CD days_NNS prior_RB to_TO 30_CD April_NNP 2002_CD ,_, being_VBG the_DT date_NN that_IN the_DT Group_NNP notified_VBN DRC_NNP that_IN they_PRP intended_VBD to_TO terminate_VB the_DT royalty_NN agreement_NN ._.
This_DT resulted_VBD in_IN a_DT credit_NN to_TO the_DT share_NN premium_NN account_NN of_IN 6,102,000_CD ._.
Under_IN US_NNP GAAP_NNP the_DT share_NN price_NN applied_VBD was_VBD the_DT fair_JJ value_NN of_IN the_DT closing_NN CAT_NNP share_NN price_NN on_IN the_DT 30_CD April_NNP 2002_CD ,_, resulting_VBG in_IN a_DT credit_NN to_TO the_DT share_NN premium_NN account_NN of_IN 5,379,000_CD ._.
h_NNP Foreign_NNP currency_NN translation_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT results_NNS of_IN overseas_JJ subsidiaries_NNS are_VBP translated_VBN at_IN the_DT closing_NN exchange_NN rate_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT average_JJ exchange_NN rate_NN for_IN the_DT year_NN is_VBZ used_VBN ._.
64_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD i_FW Taxation_NNP ._.
Under_IN UK_NNP GAAP_NNP ,_, deferred_VBN tax_NN is_VBZ provided_VBN in_IN full_JJ on_IN timing_NN differences_NNS which_WDT result_VBP in_IN an_DT obligation_NN at_IN the_DT balance_NN sheet_NN date_NN to_TO pay_VB more_JJR tax_NN ,_, or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN ,_, at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN rates_NNS and_CC law_NN ._.
Net_JJ deferred_VBN tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, deferred_VBN tax_NN is_VBZ recognized_VBN in_IN full_JJ in_IN respect_NN of_IN temporary_JJ differences_NNS between_IN the_DT reported_VBN carrying_VBG amount_NN of_IN an_DT asset_NN or_CC liability_NN and_CC its_PRP$ corresponding_JJ tax_NN basis_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP also_RB recognized_VBN in_IN full_JJ subject_NN to_TO a_DT valuation_NN allowance_NN to_TO reduce_VB the_DT amount_NN of_IN such_JJ assets_NNS to_TO that_DT which_WDT is_VBZ more_RBR likely_JJ than_IN not_RB to_TO be_VB realized_VBN ._.
As_IN at_IN 30_CD September_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD ,_, CAT_NNP has_VBZ approximately_RB 79_CD million_CD ,_, 60_CD million_CD and_CC 36_CD million_CD respectively_RB of_IN cumulative_JJ tax_NN losses_NNS ._.
These_DT losses_NNS represent_VBP a_DT deferred_JJ tax_NN asset_NN for_IN accounting_NN purposes_NNS ._.
In_IN accordance_NN with_IN both_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP ,_, no_DT asset_NN has_VBZ been_VBN recognized_VBN in_IN respect_NN of_IN these_DT tax_NN losses_NNS due_JJ to_TO the_DT uncertainty_NN as_IN to_TO whether_IN these_DT losses_NNS can_MD be_VB offset_VBN against_IN future_JJ profits_NNS ._.
No_DT tax_NN effect_NN has_VBZ been_VBN recognized_VBN in_IN the_DT reconciliation_NN of_IN net_JJ loss_NN from_IN UK_NNP GAAP_NNP to_TO US_NNP GAAP_NNP in_IN respect_NN of_IN the_DT differences_NNS arising_VBG in_IN respect_NN of_IN those_DT items_NNS ,_, as_IN the_DT timing_NN differences_NNS arising_VBG are_VBP offset_VBN in_IN full_JJ by_IN the_DT unrecognised_JJ tax_NN losses_NNS carried_VBD forward_RB ._.
Consolidated_NNP statements_NNS of_IN cash_NN flows_VBZ The_DT consolidated_JJ statements_NNS of_IN cash_NN flows_NNS prepared_VBN under_IN UK_NNP GAAP_NNP presents_VBZ substantially_RB the_DT same_JJ information_NN as_IN that_DT required_VBN under_IN US_NNP GAAP_NNP by_IN SFAS_NNP 95_CD Statement_NN of_IN Cash_NNP Flows_NNP ._.
These_DT standards_NNS differ_VBP however_RB with_IN regard_NN to_TO classification_NN of_IN items_NNS within_IN the_DT statements_NNS and_CC the_DT definition_NN of_IN cash_NN and_CC cash_NN equivalents_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, cash_NN comprises_VBZ only_RB cash_NN in_IN hand_NN and_CC deposits_NNS repayable_JJ on_IN demand_NN ._.
Deposits_NNS are_VBP repayable_JJ on_IN demand_NN if_IN they_PRP can_MD be_VB withdrawn_VBN at_IN any_DT time_NN without_IN notice_NN and_CC without_IN penalty_NN or_CC if_IN a_DT maturity_NN or_CC period_NN of_IN notice_NN of_IN not_RB more_JJR than_IN 24_CD hours_NNS or_CC one_CD working_VBG day_NN has_VBZ been_VBN agreed_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, cash_NN equivalents_NNS are_VBP short_JJ term_NN highly_RB liquid_JJ investments_NNS ,_, generally_RB with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ,_, that_WDT are_VBP readily_RB convertible_JJ to_TO known_JJ amounts_NNS of_IN cash_NN and_CC present_JJ insignificant_JJ risk_NN of_IN changes_NNS in_IN value_NN because_IN of_IN changes_NNS in_IN interest_NN rates_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, cash_NN flows_NNS are_VBP presented_VBN separately_RB for_IN operating_VBG activities_NNS ,_, returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN ,_, taxation_NN ,_, capital_NN expenditure_NN and_CC financial_JJ investment_NN ,_, management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN activities_NNS ._.
US_NNP GAAP_NNP requires_VBZ only_RB three_CD categories_NNS of_IN cash_NN flow_NN activity_NN to_TO be_VB reported_VBN :_: operating_NN ,_, investing_VBG and_CC financing_VBG ._.
Cash_NN flows_VBZ from_IN taxation_NN and_CC returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN under_IN UK_NNP GAAP_NNP would_MD ,_, with_IN the_DT exception_NN of_IN dividends_NNS paid_VBN ,_, be_VB shown_VBN under_IN operating_VBG activities_NNS under_IN US_NNP GAAP_NNP ._.
The_DT payment_NN of_IN dividends_NNS and_CC the_DT payment_NN to_TO acquire_VB own_JJ shares_NNS treasury_NN stock_NN would_MD be_VB included_VBN as_IN a_DT financing_NN activity_NN under_IN US_NNP GAAP_NNP ._.
Management_NN of_IN liquid_JJ resources_NNS under_IN UK_NNP GAAP_NNP would_MD be_VB included_VBN as_IN cash_NN and_CC cash_NN equivalents_NNS ._.
Under_IN US_NNP GAAP_NNP management_NN of_IN liquid_JJ resources_NNS would_MD be_VB included_VBN to_TO the_DT extent_NN that_IN the_DT amounts_NNS involved_VBN have_VBP a_DT maturity_NN of_IN less_JJR than_IN three_CD months_NNS and_CC are_VBP convertible_JJ into_IN known_JJ amounts_NNS of_IN cash_NN ._.
Summary_JJ statements_NNS of_IN cash_NN flow_NN presented_VBN under_IN US_NNP GAAP_NNP are_VBP given_VBN below_IN :_: 2002 2001 2000 000_CD 000_CD 000_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN operating_VBG activities_NNS 18,330_CD 10,828_CD 636_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 5,106_CD 21,735_CD 32,725_CD Net_JJ cash_NN provided_VBN by_IN financing_VBG activities_NNS 1,448_CD 15,380_CD 132,293_CD Effects_NNPS of_IN exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS 32_CD 2_CD Decrease_NN increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 22,020_CD 17,183_CD 100,206_CD Beginning_NN cash_NN and_CC cash_NN equivalents_NNS 90,599_CD 107,782_CD 7,576_CD Ending_NNP cash_NN and_CC cash_NN equivalents_NNS 68,579_CD 90,599_CD 107,782_CD 65_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD A_DT reconciliation_NN between_IN the_DT consolidated_JJ cash_NN flow_NN statement_NN prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP is_VBZ presented_VBN below_IN for_IN the_DT years_NNS ended_VBN 30_CD September_NNP :_: 2002 2001 2000 000_CD 000_CD 000_CD Operating_NN activities_NNS Net_JJ cash_NN used_VBN in_IN operating_VBG activities_NNS under_IN UK_NNP GAAP_NNP 26,808_CD 19,150_CD 3,609_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 7,558_CD 8,322_CD 4,245_CD Taxation_NNP 920_CD Net_JJ cash_NN used_VBN in_IN operating_VBG activities_NNS under_IN US_NNP GAAP_NNP 18,330_CD 10,828_CD 636_CD Investing_VBG activities_NNS Capital_NNP expenditure_NN and_CC financial_JJ investment_NN under_IN UK_NNP GAAP_NNP 9,961_CD 3,481_CD 974_CD Management_NN of_IN liquid_JJ resources_NNS under_IN UK_NNP GAAP_NNP 29,534_CD 274_CD 133,729_CD Cash_NN equivalents_NNS with_IN a_DT maturity_NN of_IN less_JJR than_IN three_CD months_NNS 24,679_CD 18,528_CD 101,978_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 5,106_CD 21,735_CD 32,725_CD Movement_NNP in_IN cash_NN Increase_VBP decrease_NN in_IN cash_NN under_IN UK_NNP GAAP_NNP 2,691_CD 1,345_CD 1,774_CD Cash_NN equivalents_NNS with_IN a_DT maturity_NN of_IN less_JJR than_IN three_CD months_NNS 24,679_CD 18,528_CD 101,978_CD Effects_NNPS of_IN exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS 32_CD 2_CD 22,020_CD 17,183_CD 100,206_CD Accounting_NN for_IN share-based_JJ compensation_NN As_IN permitted_VBN under_IN SFAS_NNP 123_CD ,_, Accounting_NNP for_IN Stock-Based_NNP Compensation_NNP ,_, in_IN accounting_NN for_IN options_NNS granted_VBN under_IN its_PRP$ share_NN option_NN schemes_NNS the_DT Group_NNP has_VBZ adopted_VBN the_DT disclosure_NN provisions_NNS of_IN SFAS_NNP 123_CD ,_, but_CC opted_VBD to_TO remain_VB under_IN the_DT expense_NN recognition_NN provisions_NNS of_IN APB_NNP Opinion_NNP 25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS ._.
Accordingly_RB ,_, for_IN the_DT years_NNS ended_VBN 30_CD September_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD ,_, compensation_NN expenses_NNS of_IN 3,703,000_CD ,_, 7,804,000_CD and_CC 8,223,000_CD were_VBD recognized_VBN for_IN options_NNS granted_VBN under_IN these_DT schemes_NNS ._.
Had_VBD compensation_NN expense_NN for_IN options_NNS granted_VBN under_IN these_DT schemes_NNS been_VBN determined_VBN based_VBN on_IN fair_JJ value_NN at_IN the_DT grant_NN dates_NNS in_IN accordance_NN with_IN SFAS_NNP 123_CD ,_, the_DT Companys_NNP charge_NN to_TO income_NN for_IN the_DT years_NNS ending_VBG 30_CD September_NNP 2002_CD ,_, 2001_CD and_CC 2000_CD would_MD have_VB been_VBN 1,523,000_CD ,_, 1,064,000_CD and_CC 814,000_CD respectively_RB ._.
In_IN calculating_VBG these_DT amounts_NNS ,_, the_DT fair_JJ value_NN of_IN the_DT options_NNS has_VBZ been_VBN amortised_VBN over_IN their_PRP$ respective_JJ vesting_NN periods_NNS ._.
Net_JJ loss_NN and_CC loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP would_MD therefore_RB have_VB been_VBN reduced_VBN to_TO the_DT pro_FW forma_FW amounts_VBZ shown_VBN below_IN :_: 2002 2001 2000 000_CD 000_CD 000_CD Pro_FW forma_FW net_JJ loss_NN 29,111_CD 12,825_CD 9,722_CD Pro_FW forma_FW net_JJ loss_NN per_IN share_NN basic_JJ and_CC fully_RB diluted_VBN 81.3_CD p_NN 36.3_CD p_NN 32.2_CD p_VBP Reported_VBN net_JJ loss_NN 31,291_CD 19,565_CD 17,131_CD Reported_VBN net_JJ loss_NN per_IN share_NN basic_JJ and_CC fully_RB diluted_VBN 87.3_CD p_NN 55.4_CD p_VBP 56.8_CD p_JJ The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS was_VBD estimated_VBN using_VBG the_DT Black-Scholes_NNP stock_NN option_NN pricing_NN model_NN using_VBG the_DT following_VBG weighted_JJ average_JJ assumptions_NNS :_: Annual_JJ standard_JJ Risk-free_JJ Expected_VBN life_NN Year_NN ending_VBG Dividend_NN yield_NN deviation_NN volatility_NN interest_NN rate_NN Years_NNS 30_CD September_NNP 2002_CD 0_CD %_NN 65_CD %_NN 4.9_CD %_NN 5.5_CD 30_CD September_NNP 2001_CD 0_CD %_NN 75_CD %_NN 5.3_CD %_NN 5.5_CD 30_CD September_NNP 2000_CD 0_CD %_NN 75_CD %_NN 6.1_CD %_NN 5.5_CD 66_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD For_IN the_DT purposes_NNS of_IN the_DT following_VBG tabulations_NNS ,_, Weighted_NNP Average_NNP Exercise_NNP Price_NNP is_VBZ abbreviated_JJ to_TO WAEP_NNP ,_, Weighted_NNP Average_NNP Fair_NNP Value_NNP to_TO WAFV_NNP and_CC Weighted_NNP Average_NNP Remaining_VBG Contractual_NNP Life_NNP to_TO WARCL_NNP ._.
Exercisable_JJ as_IN at_IN Outstanding_JJ as_IN at_IN 30_CD September_NNP 2002_CD 30_CD September_NNP 2002_CD Range_NNP of_IN exercise_NN prices_NNS WAEP_NNP WARCL_NNP WAEP_NNP Number_NNP Years_NNS Number_NN 0_CD 0.99_CD 1_CD 2.99_CD 699,450_CD 2.66_CD 4.32_CD 224,718_CD 2.20_CD 3_CD 4.99_CD 189,179_CD 3.06_CD 3.78_CD 189,179_CD 3.06_CD 5_CD 9.99_CD 249,760_CD 5.02_CD 3.79_CD 249,760_CD 5.02_CD 10_CD 19.99_CD 269,883_CD 14.88_CD 9.34_CD 20_CD 31_CD 93,535_CD 29.46_CD 6.33_CD Total_JJ 1,501,807_CD 6.97_CD 5.19_CD 663,657_CD 3.51_CD Exercisable_JJ as_IN at_IN Outstanding_JJ as_IN at_IN 30_CD September_NNP 2001_CD 30_CD September_NNP 2001_CD Range_NNP of_IN exercise_NN prices_NNS WAEP_NNP WARCL_NNP WAEP_NNP Number_NNP Years_NNS Number_NN 0_CD 0.99_CD 1_CD 2.99_CD 766,149_CD 2.63_CD 5.26_CD 45,350_CD 1.28_CD 3_CD 4.99_CD 374,924_CD 3.03_CD 4.21_CD 357,929_CD 3.03_CD 5_CD 10_CD 277,760_CD 5.02_CD 4.84_CD 260,260_CD 5.02_CD 21_CD 31_CD 99,145_CD 29.49_CD 7.29_CD Total_JJ 1,517,978_CD 4.92_CD 3.95_CD 663,539_CD 3.69_CD 67_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD Exercisable_JJ as_IN at_IN Outstanding_JJ as_IN at_IN 30_CD September_NNP 2000_CD 30_CD September_NNP 2000_CD Range_NNP of_IN exercise_NN prices_NNS WAEP_NNP WARCL_NNP WAEP_NNP Number_NNP Years_NNS Number_NN 0_CD 0.99_CD 1_CD 2.99_CD 870,470_CD 2.49_CD 6.10_CD 137,794_CD 1.31_CD 3_CD 4.99_CD 434,253_CD 3.03_CD 5.31_CD 417,258_CD 3.03_CD 5_CD 10_CD 488,660_CD 5.01_CD 5.88_CD 148,860_CD 5.03_CD 21_CD 31_CD 3,264_CD 23.03_CD 9.65_CD Total_JJ 1,796,647_CD 3.34_CD 5.76_CD 703,912_CD 3.12_CD Deferred_JJ tax_NN A_DT reconciliation_NN of_IN the_DT provision_NN for_IN income_NN taxes_NNS with_IN the_DT amount_NN computed_VBN by_IN applying_VBG the_DT statutory_JJ income_NN tax_NN rate_NN 30_CD %_NN for_IN 2002_CD and_CC 2001_CD and_CC 30.2_CD %_NN for_IN 2000_CD to_TO loss_NN before_IN taxation_NN ,_, using_VBG UK_NNP GAAP_NNP measurement_NN principles_NNS ,_, is_VBZ as_IN follows_VBZ :_: 2002 2001 2000 000_CD 000_CD 000_CD Income_NNP tax_NN expense_NN computed_VBD at_IN statutory_JJ income_NN tax_NN rate_NN 9,529_CD 3,531_CD 2,503_CD Permanent_JJ differences_NNS 1,041_CD 1,205_CD 549_CD Utilisation_NN of_IN tax_NN losses_NNS in_IN respect_NN of_IN research_NN and_CC development_NN tax_NN credit_NN claimed_VBD 3,557_CD Other_JJ 164_CD Change_NNP in_IN valuation_NN allowance_NN 10,570_CD 4,736_CD 3,216_CD Credit_NN for_IN income_NN taxes_NNS 3,557_CD Net_JJ deferred_JJ taxes_NNS are_VBP analyzed_VBN as_IN follows_VBZ :_: 2002 2001 2000 000_CD 000_CD 000_CD Deferred_JJ tax_NN assets_NNS :_: Losses_NNS carried_VBD forward_RB 23,658_CD 18,126_CD 13,108_CD Excess_NNPS of_IN tax_NN value_NN over_IN book_NN value_NN of_IN fixed_JJ assets_NNS 335_CD 599_CD Other_JJ short_JJ term_NN timing_NN differences_NNS 58_CD 23_CD 23,716_CD 18,461_CD 13,730_CD Valuation_NN allowance_NN 22,444_CD 18,461_CD 13,725_CD Net_JJ deferred_JJ tax_NN asset_NN 1,272_CD 5_CD Deferred_JJ tax_NN liabilities_NNS :_: Other_JJ short_JJ term_NN timing_NN differences_NNS 5_CD Excess_NN of_IN book_NN value_NN over_IN tax_NN value_NN of_IN fixed_JJ assets_NNS 1,272_CD Net_JJ deferred_JJ taxes_NNS As_IN discussed_VBN in_IN Note_NN 7_CD ,_, the_DT Group_NNP recorded_VBD a_DT research_NN and_CC development_NN tax_NN credit_NN in_IN the_DT current_JJ year_NN ._.
This_DT credit_NN results_NNS in_IN a_DT surrender_NN of_IN certain_JJ lossses_NNS for_IN which_WDT a_DT valuation_NN allowance_NN was_VBD recorded_VBN in_IN the_DT prior_JJ year_NN ._.
The_DT change_NN in_IN valuation_NN allowance_NN above_IN includes_VBZ the_DT establishment_NN of_IN the_DT valuation_NN allowance_NN for_IN the_DT current_JJ year_NN and_CC the_DT decrease_NN in_IN the_DT valuation_NN allowance_NN resulting_VBG from_IN the_DT surrender_NN of_IN prior_JJ year_NN losses_NNS ._.
The_DT Group_NNP ,_, to_TO the_DT extent_NN it_PRP is_VBZ eligible_JJ ,_, will_MD continue_VB to_TO record_VB research_NN and_CC development_NN tax_NN credits_NNS in_IN the_DT period_NN in_IN which_WDT they_PRP become_VBP estimable_JJ ._.
As_IN at_IN 30_CD September_NNP 2002_CD the_DT Group_NNP had_VBD approximately_RB 79_CD million_CD of_IN tax_NN losses_NNS available_JJ to_TO carry_VB forward_RB indefinitely_RB against_IN future_JJ trading_NN profits_NNS ._.
68_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 27_CD Reconciliation_NNP to_TO US_NNP GAAP_NNP continued_VBD Recently_RB issued_VBN accounting_NN pronouncements_NNS In_IN August_NNP 2001_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP issued_VBD SFAS_NNP 144_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS ,_, which_WDT addresses_VBZ financial_JJ accounting_NN and_CC reporting_VBG for_IN the_DT impairment_NN or_CC disposal_NN of_IN Long-Lived_NNP Assets_NNPS and_CC supersedes_NNS SFAS_NNP 121_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN of_IN Long-Lived_NNP Assets_NNPS and_CC for_IN Long-Lived_NNP Assets_NNPS to_TO be_VB Disposed_VBN Of_IN ,_, and_CC the_DT accounting_NN and_CC reporting_NN provisions_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
30_CD ,_, Reporting_NNP the_DT Results_NNS of_IN Operations_NNP ,_, for_IN a_DT disposal_NN of_IN a_DT segment_NN of_IN a_DT business_NN ._.
SFAS_NNP 144_CD is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD December_NNP 2001_CD ,_, with_IN earlier_JJR application_NN encouraged_VBD ._.
We_PRP expect_VBP to_TO adopt_VB SFAS_NNP 144_CD as_IN of_IN 1_CD October_NNP 2002_CD and_CC we_PRP do_VBP not_RB expect_VB that_IN the_DT adoption_NN of_IN the_DT Statement_NNP will_MD have_VB a_DT significant_JJ impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
In_IN April_NNP 2002_CD the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP issued_VBD SFAS_NNP 145_CD ,_, Rescission_NNP of_IN FASB_NNP Statements_NNP No._NN ._.
64_CD ,_, Amendment_NNP to_TO FASB_NNP Statement_NNP No._NN ._.
SFAS_NNP 145_CD streamlines_NNS the_DT reporting_NN of_IN debt_NN extinguishments_NNS and_CC requires_VBZ that_IN only_RB gains_NNS and_CC loses_VBZ from_IN extinguishments_NNS meeting_VBG the_DT criteria_NNS in_IN Accounting_NNP Policies_NNS Board_NNP Opinion_NNP 30_CD would_MD be_VB classified_VBN as_IN extraordinary_JJ ._.
Thus_RB ,_, gains_NNS and_CC losses_NNS arising_VBG from_IN extinguishments_NNS that_WDT are_VBP part_NN of_IN a_DT companys_NNS recurring_VBG operations_NNS would_MD not_RB be_VB reported_VBN as_IN an_DT extraordinary_JJ item_NN ._.
SFAS_NNP 145_CD is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD May_NNP 2002_CD with_IN earlier_JJR adoption_NN encouraged_VBD ._.
We_PRP do_VBP not_RB expect_VB the_DT adoption_NN of_IN SFAS_NNP 145_CD to_TO have_VB a_DT material_NN impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
SFAS_NNP 146_CD ,_, Accounting_NNP for_IN Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NNP Activities_NNP was_VBD issued_VBN in_IN June_NNP 2002_CD and_CC addresses_NNS accounting_NN and_CC processing_NN for_IN costs_NNS associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS and_CC nullifies_NNS Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP Issue_NNP 94-3_CD ,_, Liability_NN Recognition_NN for_IN Certain_NNP Employee_NNP Termination_NN Benefits_NNS and_CC Other_JJ Costs_NNS to_TO Exit_NN and_CC Activity_NN including_VBG Certain_NNP Costs_NNS Incurred_VBN in_IN a_DT Restructuring_NN ._.
SFAS_NNP 146_CD requires_VBZ that_IN a_DT liability_NN for_IN a_DT cost_NN associated_VBN with_IN an_DT exit_NN or_CC disposal_NN liability_NN be_VB recognized_VBN when_WRB the_DT liability_NN is_VBZ incurred_VBN ._.
Under_IN Issue_NNP 94-3_CD ,_, a_DT liability_NN for_IN an_DT exit_NN cost_NN was_VBD recognized_VBN at_IN the_DT date_NN of_IN an_DT entitys_JJ commitment_NN to_TO an_DT exit_NN plan_NN ._.
Under_IN SFAS_NNP 146_CD ,_, fair_JJ value_NN is_VBZ the_DT objective_NN for_IN initial_JJ measurement_NN of_IN the_DT liability_NN ._.
SFAS_NNP 146_CD is_VBZ effective_JJ for_IN exit_NN or_CC disposal_NN activities_NNS that_WDT are_VBP initiated_VBN after_IN 31_CD December_NNP 2002_CD ,_, with_IN early_JJ application_NN encouraged_VBD ._.
We_PRP do_VBP not_RB expect_VB the_DT adoption_NN of_IN SFAS_NNP 146_CD to_TO have_VB a_DT material_NN impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
In_IN 2001_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP issued_VBD SFAS_NNP 141_CD ,_, Business_NNP Combinations_NNPS and_CC SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
SFAS_NNP 141_CD requires_VBZ the_DT use_NN of_IN the_DT purchase_NN method_NN of_IN accounting_NN for_IN all_DT business_NN combinations_NNS initiated_VBN after_IN 30_CD June_NNP 2001_CD ._.
SFAS_NNP 141_CD requires_VBZ intangible_JJ assets_NNS to_TO be_VB recognized_VBN if_IN they_PRP arise_VBP from_IN contractual_JJ or_CC legal_JJ rights_NNS or_CC are_VBP separable_JJ ,_, ie_NN ,_, it_PRP is_VBZ feasible_JJ that_IN they_PRP may_MD be_VB sold_VBN ,_, transferred_VBN ,_, licensed_VBN ,_, rented_VBN ,_, exchanged_VBD or_CC pledged_VBD ._.
As_IN a_DT result_NN ,_, it_PRP is_VBZ likely_JJ that_IN more_JJR intangible_JJ assets_NNS will_MD be_VB recognized_VBN under_IN SFAS_NNP 141_CD than_IN its_PRP$ predecessor_NN ,_, APB_NNP Opinion_NNP 16_CD ,_, although_IN in_IN some_DT instances_NNS previously_RB recognized_VBN intangibles_NNS will_MD be_VB subsumed_VBN into_IN goodwill_NN ._.
Under_IN SFAS_NNP 142_CD ,_, goodwill_NN will_MD no_RB longer_RB be_VB amortised_VBN on_IN a_DT straight_JJ line_NN basis_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN ,_, but_CC will_MD be_VB tested_VBN for_IN impairment_NN on_IN an_DT annual_JJ basis_NN and_CC whenever_WRB indicators_NNS of_IN impairment_NN arise_VB ._.
The_DT goodwill_NN impairment_NN test_NN ,_, which_WDT is_VBZ based_VBN on_IN fair_JJ value_NN ,_, is_VBZ to_TO be_VB performed_VBN on_IN a_DT reporting_VBG unit_NN level_NN ._.
A_DT reporting_VBG unit_NN is_VBZ defined_VBN as_IN a_DT SFAS_NNP 131_CD operating_VBG segment_NN or_CC one_CD level_NN lower_JJR ._.
Goodwill_NN will_MD no_RB longer_RB be_VB allocated_VBN to_TO other_JJ long-lived_JJ assets_NNS for_IN impairment_NN testing_NN under_IN SFAS_NNP 121_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN of_IN Long-Lived_NNP Assets_NNPS and_CC for_IN Long-Lived_NNP Assets_NNPS to_TO be_VB Disposed_VBN Of_IN ._.
Additionally_RB ,_, goodwill_NN on_IN equity_NN method_NN investments_NNS will_MD no_RB longer_RB be_VB amortised_VBN :_: however_RB ,_, it_PRP will_MD continue_VB to_TO be_VB tested_VBN for_IN impairment_NN in_IN accordance_NN with_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP 18_CD ,_, The_DT Equity_NNP Method_NNP of_IN Accounting_NNP for_IN Investments_NNP in_IN Common_NNP Stock_NNP ._.
Under_IN SFAS_NNP 142_CD intangible_JJ assets_NNS with_IN indefinite_JJ lives_NNS will_MD not_RB be_VB amortised_VBN ._.
Instead_RB they_PRP will_MD be_VB carried_VBN at_IN the_DT lower_JJR of_IN cost_NN or_CC market_NN value_NN and_CC tested_VBN for_IN impairment_NN at_IN least_JJS annually_RB ._.
All_DT other_JJ recognized_VBN intangible_JJ assets_NNS will_MD continue_VB to_TO be_VB amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS ._.
SFAS_NNP 142_CD is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD December_NNP 2001_CD although_IN goodwill_NN on_IN business_NN combinations_NNS consummated_VBN after_IN 1_CD July_NNP 2001_CD will_MD not_RB be_VB amortised_VBN ._.
The_DT adoption_NN of_IN SFAS_NNP 141_CD and_CC 142_CD is_VBZ not_RB expected_VBN to_TO have_VB any_DT material_NN impact_NN upon_IN the_DT Groups_NNS results_NNS ._.
